Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by bacteria that have antigenic activity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by viruses that have antigenic activity.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Substances of fungal origin that have antigenic activity.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
The major group of transplantation antigens in the mouse.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Antibodies produced by a single clone of cells.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
Sites on an antigen that interact with specific antibodies.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Established cell cultures that have the potential to propagate indefinitely.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
One of four subsections of the hippocampus described by Lorente de No, located furthest from the DENTATE GYRUS.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
A subsection of the hippocampus, described by Lorente de No, that is located between the HIPPOCAMPUS CA2 FIELD and the DENTATE GYRUS.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Cation-transporting proteins that utilize the energy of ATP hydrolysis for the transport of CALCIUM. They differ from CALCIUM CHANNELS which allow calcium to pass through a membrane without the use of energy.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The sum of the weight of all the atoms in a molecule.
A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions.
Elements of limited time intervals, contributing to particular results or situations.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Proteins prepared by recombinant DNA technology.
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
An encapsulated lymphatic organ through which venous blood filters.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
A sesquiterpene lactone found in roots of THAPSIA. It inhibits CA(2+)-TRANSPORTING ATPASE mediated uptake of CALCIUM into SARCOPLASMIC RETICULUM.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
An electrogenic ion exchange protein that maintains a steady level of calcium by removing an amount of calcium equal to that which enters the cells. It is widely distributed in most excitable membranes, including the brain and heart.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and nonexcitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Diagnostic procedures involving immunoglobulin reactions.
Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
Immunoglobulins produced in a response to HELMINTH ANTIGENS.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Glycoproteins found on the membrane or surface of cells.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
An increased reactivity to specific antigens mediated not by antibodies but by cells.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Immunologically detectable substances found in the CELL NUCLEUS.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Antigens produced by various strains of HEPATITIS D VIRUS.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
Agents that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags.
A tetrameric calcium release channel in the SARCOPLASMIC RETICULUM membrane of SMOOTH MUSCLE CELLS, acting oppositely to SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES. It is important in skeletal and cardiac excitation-contraction coupling and studied by using RYANODINE. Abnormalities are implicated in CARDIAC ARRHYTHMIAS and MUSCULAR DISEASES.
A major histocompatibily complex class I-like protein that plays a unique role in the presentation of lipid ANTIGENS to NATURAL KILLER T-CELLS.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*01 allele family.
Polysaccharides found in bacteria and in capsules thereof.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Intracellular receptors that bind to INOSITOL 1,4,5-TRISPHOSPHATE and play an important role in its intracellular signaling. Inositol 1,4,5-trisphosphate receptors are calcium channels that release CALCIUM in response to increased levels of inositol 1,4,5-trisphosphate in the CYTOPLASM.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*07 allele family.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*04 alleles.
A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Tumors or cancer of the PROSTATE.
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*03 alleles.
Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Proteins found in any species of bacterium.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
The rate dynamics in chemical or physical systems.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*24 allele family.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Paracrine changes in the peritoneal environment of women with endometriosis. (1/616)

During the past decade, macrophage-derived substances such as prostanoids, cytokines, growth factors and angiogenic factors have been detected in the peritoneal fluid of women with endometriosis. In particular, growth-promoting and angiogenic factors are considered to be substantially involved in the pathogenesis of endometriosis. In this study, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-beta) and intercellular adhesion molecule 1 (ICAM-1), substances recently detected in the peritoneal fluid of women with endometriosis, were assessed with regard to their concentrations in different stages of endometriosis and changes of the peritoneal paracrine activity after medical treatment with a gonadotrophin releasing hormone agonist (GnRHa). Peritoneal fluid was obtained from patients with endometriosis during laparoscopy before and after a 4-month treatment with a GnRHa. VEGF, TGF-beta and ICAM-1 could be detected in all women presenting with various stages of active endometriosis. After GnRHa therapy, all patients showed significant decreases in mean concentrations of VEGF (194+/-77 pg/ml), TGF-beta (902+/-273 pg/ml) and ICAM-1 (157+/-52 ng/ml). Patients with stage III and IV endometriosis (according to the rAFS score) had much higher concentrations of VEGF and TGF-beta before treatment compared with those patients with mild endometriosis (rAFS stages I and II). The most striking decrease in concentration was for TGF-beta, from 902 pg/ml before to 273 pg/ml after therapy. These results indicate an important role for paracrine activity in the establishment and maintenance of endometriosis. Indeed, treatment with a GnRHa may reduce paracrine activity in the peritoneal cavity via hypo-oestrogenism and provide proof of successful therapy.  (+info)

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. (2/616)

PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel. PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived from four different trials and 625 patients treated with platinum from two trials were analyzed using precisely defined 50% and 75% reductions in CA-125. The standard and CA-125 response rates to paclitaxel and platinum were compared. In addition, we analyzed individual patient groups in which there was a difference in response according to the two response criteria. RESULTS: Patients with stable disease as determined by standard criteria who were treated with platinum and responded according to CA-125 criteria have an improved median progression-free survival compared with patients with stable disease who did not respond according to CA-125 criteria (10.6 v 4.8 months; P<.001). Standard and CA-125 response rates for patients treated with platinum (58.93% v 61.31%, respectively) and paclitaxel (30.65% v 31.67%, respectively) were very similar, as were rates of false-positive prediction of response by CA-125 (platinum 2.2% and paclitaxel 2.9%). Responders to paclitaxel had a significantly improved progression-free survival compared with non-responders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P<.001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P<.001). CONCLUSION: Forassessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria. We propose that they may be used as a measure of response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer. Sensitivity is maintained whether patients are treated with platinum or paclitaxel.  (+info)

Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. (3/616)

The aim of this study was to investigate cycle dependent changes of serum CA 125 and CA 15-3 concentrations during spontaneous ovulatory cycles. Twenty apparently healthy women with spontaneous menstrual cycles attending our infertility clinic were included. Of these women, 18 had occluded tubes as a result of sterilization. Ovulation was confirmed by luteinizing hormone test and ultrasonography and, to exclude endometriosis, a laparoscopy was performed. Serum samples for CA 125, CA 15-3, 17 beta-oestradiol and progesterone determinations were taken every second day starting on the 2nd day of the cycle until the 7th day of the next cycle. After correction for inter-individual variation in serum concentrations, highest CA 125 concentrations were found during the menstruation. During the follicular and peri-ovulatory phase CA 125 serum concentrations were lowest. For CA 15-3, serum concentrations were not statistically different throughout the cycle. CA 125 and oestradiol concentrations were negatively correlated, CA 15-3 and oestradiol concentrations were positively correlated. Absolute serum concentrations of both CA 125 and CA 15-3 vary among females. Within the female, fluctuations of CA 125 are phase related. In the population studied most of the patients had tubal obstruction and high CA 125 serum concentrations during menstruation, which revokes the theory that the menstrual rise of CA 125 is due only to retrograde menstruation.  (+info)

Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. (4/616)

OBJECTIVE: The aim of this study was to generate and evaluate artificial neural network (ANN) models from simple clinical and ultrasound-derived criteria to predict whether or not an adnexal mass will have histological evidence of malignancy. DESIGN: The data were collected prospectively from 173 consecutive patients who were scheduled to undergo surgical investigations at the University Hospitals, Leuven, between August 1994 and August 1996. The outcome measure was the histological classification of excised tissues as malignant (including borderline) or benign. METHODS: Age, menopausal status and serum CA 125 levels and sonographic features of the adnexal mass were encoded as variables. The ANNs were trained on a randomly selected set of 116 patient records and tested on the remainder (n = 57). The performance of each model was evaluated using receiver operating characteristic (ROC) curves and compared with corresponding data from an established risk of malignancy index (RMI) and a logistic regression model. RESULTS: There were 124 benign masses, five of borderline malignancy and 44 invasive cancers (of which 29% were metastatic); 37% of patients with a malignant or borderline tumor had stage I disease. The best ANN gave an area under the ROC curve of 0.979 for the whole dataset, a sensitivity of 95.9% and specificity of 93.5%. The corresponding values for the RMI were 0.882, 67.3% and 91.1%, and for the logistic regression model 0.956, 95.9% and 85.5%, respectively. CONCLUSION: An ANN can be trained to provide clinically accurate information, on whether or not an adnexal mass is malignant, from the patient's menopausal status, serum CA 125 levels, and some simple ultrasonographic criteria.  (+info)

Combined inhibin and CA125 assays in the detection of ovarian cancer. (5/616)

BACKGROUND: The reproductive hormone inhibin has been used as a diagnostic marker of ovarian mucinous and granulosa cell cancers. The aims of this study were to develop a new inhibin immunofluorometric assay (alphaC IFMA) to replace an inhibin RIA as a diagnostic marker of these ovarian cancers and to assess whether the alphaC IFMA in combination with CA125, which detects serous cancers, leads to an improved biochemical diagnosis of all ovarian cancers. METHODS: Serum inhibin concentrations were determined in healthy postmenopausal women (n = 165) and women with ovarian cancers (n = 154), using an inhibin RIA and an alphaC IFMA, which detects inhibin forms containing the alphaC subunit as well as the free alphaC subunit. RESULTS: The alphaC IFMA gave a similar or better discrimination of mucinous (90% vs 71%) and granulosa cell (100% vs 100%) cancers compared with the inhibin RIA. Combination of CA125 and alphaC IFMA values by canonical variate analysis or by multiROC analysis showed that the percentage of all ovarian cancers detected was significantly increased compared with either CA125 or alphaC IFMA alone. CONCLUSIONS: The alphaC IFMA shows a similar or better specificity compared with the RIA, but with increased sensitivity. In combination with CA125, the alphaC IFMA provides an effective dual test for the detection of the majority (90%) of ovarian cancers.  (+info)

Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. (6/616)

OBJECTIVE: Several cytokines and proteins are excreted intraperitoneally during the course of peritonitis and stable states in continuous ambulatory peritoneal dialysis (CAPD) patients. Dialysate hyaluronan (HYA) is also regarded as a marker of peritoneal healing during bacterial peritonitis. We examined here, intraperitoneal HYA production in stable CAPD patients and compared the results to those of the peritoneal equilibration test (PET), the length of time on dialysis, and other marker proteins. DESIGN: We determined the concentration of HYA and other marker proteins in the 4-hour-dwell dialysate at 1-year intervals. SETTING: CAPD unit in Hitachi General Hospital. PATIENTS: The subjects were 46 stable CAPD patients who underwent 104 PETs. RESULTS: A correlation was found between the length of time on dialysis and the amount of HYA excretion in the 4-hr-dwell dialysate (r = 0.403, p < 0.001). A positive but weak correlation was found between the dialysate-to-plasma ratio of the creatinine concentration and dialysate HYA excretion (r = 0.229, p < 0.05). Seven patients were over the 90th percentile in both the concentration of HYA (>349.2 ng/mL) and the amount of HYA (>743.6 microg/4-hr dwell). Five patients exceeded 1000 microg of HYA excretion in the 4-hr-dwell dialysate, 4 of whom showed an abrupt increase of HYA excretion to more than 1000 microg/4-hr dwell, and discontinued CAPD within 6 months due to ultrafiltration failure. Two of these 4 patients were diagnosed with sclerosing encapsulating peritonitis at autopsy. CONCLUSION: Intraperitoneal HYA production increased with both higher permeable membrane and the length of time on CAPD. Monitoring of HYA in the peritoneal dialysate may be useful as a marker to assess functional and morphological changes in the peritoneum in long-term CAPD patients.  (+info)

Serum CA-125 values on the day of oocyte retrieval are not predictive of subsequent pregnancy with in-vitro fertilization. (7/616)

In the clinical management of in-vitro fertilization (IVF) patients it would be very useful to know, before the embryo transfer, whether or not there is a significant chance of pregnancy in that cycle. If low, it would be better to freeze the embryos and postpone the embryo transfer to a subsequent cycle. For this reason, a retrospective study was carried out to investigate the correlations between the serum CA-125 values before embryo transfer and the clinical outcome of that IVF cycle. Women aged <40 years undergoing a complete infertility evaluation including laparoscopy and receiving gonadotrophin-releasing hormone analogue (GnRHa) suppression followed by purified follicle stimulating hormone (FSH) for IVF-embryo transfer were entered into the study. Ninety-seven cycles qualified for evaluation (26 pregnant and 71 non-pregnant cycles). CA-125 concentrations on the day of oocyte retrieval were significantly lower in the pregnant versus non-pregnant cycles in both non-endometriosis and endometriosis patients. To evaluate the existence of a cut-off value of CA-125 which would allow the prediction of a possible pregnancy with sufficient specificity and sensitivity, a receiver operating characteristic curve analysis was performed. This analysis demonstrated the absence of any predictive value of the subsequent pregnancy for CA-125 concentrations. For this reason, and in contrast with previous findings, CA-125 determinations before the embryo transfer in IVF patients do not appear to be a useful tool for clinicians to use in predicting the outcome of IVF in any given cycle.  (+info)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. (8/616)

We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22,000 post-menopausal women, aged > or = 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 > or = 30 U ml(-1) underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02-1.12) which is similar to that of the entire population of 22,000 women (0.22%, 95% CI 0.18-0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15-37) and a significantly increased relative risk (RR) of 327 (156-683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer.  (+info)

Post-treatment alterations of serum cancer antigen 125, cancer antigen 19.9 and carcinoembryonic antigen levels in patients with gynecological malignancies in a tertiary care hospital in eastern India
Fasting Required: No Specimen: Blood Results: 1-2 Business Days Description: Cancer antigen (CA) 27.29 is used to monitor metastatic carcinoma of the...
Biological progression-free interval is defined as the interval from the date of the first administration of any study treatment to the date of the first documented serial elevation of the ovarian cancer mucin CA-125. More precisely, this is defined as the first documented increase in CA-125 levels as follows: (1) CA-125 greater than or equal to 2 times the upper level of normal (ULN) on 2 occasions at least 1 week apart (for participants with CA-125 within normal range pre-treatment) or (2) CA-125 greater than or equal to 2 times the ULN on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment and initial normalization of CA-125 on-treatment) or (3) CA-125 greater than or equal to 2 times the nadir value, which is the lowest observed CA-125 value per participant on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment which never normalized ...
OBJECTIVE: To determine whether annual screening reduces ovarian cancer mortality in women with a family history of breast or ovarian cancer. METHODS: Data was obtained from the Prostate, Lung, Colorectal, and Ovarian cancer trial, a randomized multi-center trial conducted to determine if screening could reduce mortality in these cancers. The trial enrolled 78,216 women, randomized into either a screening arm with annual serum cancer antigen 125 and pelvic ultrasounds, or usual care arm. This study identified a subgroup that reported a first degree relative with breast or ovarian cancer. Analysis was performed to compare overall mortality and disease specific mortality in the screening versus usual care arm. In patients diagnosed with ovarian cancer, stage distribution, and survival were analyzed as a secondary endpoint. RESULTS: There was no significant difference in overall mortality or disease specific mortality between the two arms. Ovarian cancer was diagnosed in 48 patients in the ...
Results. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, , , Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial., Lancet, 2010, 376, 9747, 1155-1163, doi: 10.1016/S0140-6736(10)61268-8.. ...
Quality CA-12-5 ELISA kit from ELISA kits manufacturer and elisa kits supplier : CA-12-5 ELISA Assay, CA-12-5 ELISA test, CA-125 ELISA kit, CA-125 ELISA Assay, CA-19-9 ELISA kit, CA-15-3 ELISA kit. Our kits are FDA, CE and ISO certified.
Quality CA-12-5 ELISA kit from ELISA kits manufacturer and elisa kits supplier : CA-12-5 ELISA Assay, CA-12-5 ELISA test, CA-125 ELISA kit, CA-125 ELISA Assay, CA-19-9 ELISA kit, CA-15-3 ELISA kit. Our kits are FDA, CE and ISO certified.
Standard initial treatment of ovarian cancer patients includes both surgery and chemotherapy which in the vast majority of cases achieves the disappearance of ovarian cancer lesions. This status, called clinical remission which means having no evidence of cancer on CT scan or physical examination needs to be carefully follow up in order to confirm the maintenance of the remission status or to early detect if the cancer grows again and then start a new chemotherapy. At present, no approved therapies exist for the maintenance treatment of patients who achieved the clinical remission.. This trial aims to evaluate if the repeated vaccination with Abagovomab creates an immunoresponse which is able to fight the cancer cells thus keeping the remission status as long as possible and help patients live disease-free and longer.. Patients who achieve the remission status after chemotherapy will be screened for study participation and if they meet the criteria for inclusion they will start to receive a ...
Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. (1997 ...
Elevated CA-72-4 levels are primarily used in monitoring treatment and disease course in patients with gastric cancer. In 70% of relapse cases, CA-72-4 increases prior or concurrently with clinical diagnosis of the relapse. Diagnostic sensitivity of CA-72-4 for gastric cancer increases to 66% when combination of CA-72-4,CEA,CA-125 and CA 19-9 are used. Can be elevated in ovarian and colorectal cancer ...
OncoQuest Inc. (OncoQuest or the Company), a privately held, cancer immunotherapy company today announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the Companys lead investigational drug in frontline ovarian cancer.
Alan RIACH {UK/NZ?} (M: 1957 - ?) Evans RIADORE (M: ? - 1861 Aug 18) José Antonio RIAL GONZÁLEZ {VE} (M: 1911 Apr 21 - ?) Providencia RIANCHO ESCOBALES {PR} (F: 1901 Aug 10 - ?) Prof, Nicholas (Valentine) RIASANOVSKY {US} (M: 1923 Dec 21 - 2011 May 14) Russia And West In The Teaching Of The Slavophiles [n,1952] A History Of Russia [n,1963] Prof, Carles RIBA {ES} (M: 1893 Dec 23 - 1959 Jul 12) Primer Llibre DEstances (aka: Estances) [Ca-1919] Escolis, I Altres Articles [Ca-1921] Carles Riba [?-1923] Els Marges [Ca-1927] Sis Joans [Ca-1928] Resum De Literatura Llatina [Ca-1933] Tres Suites [Ca-1937] Per Comprendre, 1927-1935 [Ca-1937] Resum De Literatura Grega [Ca-1937] Elegies De Bierville [?-1942] Del Joc I Del Foc [Ca-1946] LIngenu Amor [Ca-1948] Llegendari Català [Ca-1950] Les Aventures DEn Perot Marrasqui [Fr-1950] Salvatge Cor [p,Ca-1952] Més Els Poemes [n,Sp-1957] Esbós De Tres Oratoris [Ca-1957] Harold Uriel RIBALOW {US} (M: 1919 Jul 1 - ?) Albert RIBAUCOUR (M: 1845 Nov 28 - 1893 ...
Cancer Antigen 125 (CA-125) is a tumor marker primarily used to monitor treatment of ovarian cancer and to detect whether cancer has come back after treatment is complete. Sometimes CA-125 may be ordered to help detect early ovarian cancer in women at high risk (e.g., BRCA mutation) or to help investigate a lump in a womans lower abdominal area (pelvic mass).
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Ho on what if ca 125 doesnt change after chemo: CA 125 is not recommended as a screening tool for ovarian cancer when used in risk-based stratification. Meaning, assuming that your mom or sister didnt get diagnosed with ovarian cancer. Normal for women with endometriosis to have elevated CA-125. It sounds like your doctor has done Ultrasound to evaluate ovaries as well. Your MD knows your history and risk, likely this CA-125 level is normal
Cancer Antigen 125 (human) ELISA Kit: Colorimetric Assay for Quantitative measurement of human CA-125 in serum, plasma, urine & cell culture supernatants. Detection Range: 0.6 U/ml - 400 U/ml. 100 assays.
ca 15 3 normal range breast cancer - 28 images - ppt tumor markers powerpoint presentation id 6610494, clinical and technical evaluation of acs br serum assay of, introduction of cancer markers laboratory services, human cancer antigen ca15 3 breast cancer calibrator, ppt tumor markers powerpoint presentation id 6610494
Some labs need routine testing. Others need routine and specialty testing. With models custom-tailored to the needs of each, labs get the solution that fits their needs. The Sysmex CA-620 System offers clotting testing methodology for laboratories that primarily perform routine tests; the Sysmex CA-660 System offers clotting, chromogenic*, and immunologic* testing for laboratories that require a broader test menu and perform specialty testing.. ...
n. a tumour marker that can be detected by a simple blood test and is particularly useful in the diagnosis of ovarian cancer and also for subsequently monitoring its response to treatment. In a patient being evaluated for a pelvic mass, a CA125 level greater than 65 is associated with malignancy in approximately 90% of cases (see risk of malignancy index). A number of benign conditions, including benign ovarian tumours, can also cause elevations of the CA125 level, as can cancers other than ovarian cancer, including malignancies of the endometrium, lung, breast, and gastrointestinal tract. ...
Health, ...HOUSTON Evaluating its change over time CA-125 the protein long-rec...The updated findings are published in Cancer ; preliminary data ...MD Anderson has a long history in the research of the important biomar... Over the last ten years theres been a lot of excitement over new ma...,CA-125,change,over,time,shows,promise,as,screening,tool,for,early,detection,of,ovarian,cancer,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
CHO-Anti-Human CA-125 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CA-125 F(ab) gene to allow expression of the F(ab). It is an example of a cell line transfected using our proprietary CBTGS gene screening and amplification system.
CHO-Anti-Human CA-125 scFv stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CA-125 scFv gene to allow expression of the scFv. It is an example of a cell line transfected using our proprietary CBTGS gene screening and amplification system.
Offered on Sysmex CA-660 System only The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details. ...
CA-125 is an important part of the workup for suspicious adnexal masses and for for following treated ovarian cancer. It is not a common marker in clinical use
Get accurate and quick report of Ca 125 Test Or Cancer Antigen 125 Test in titwala at your nearest Metropolis lab or your home at affordable cost. CA 125 test is used to monitor the treatment of Ovarian Cancer. It is also used to test for recurrence of ovarian cancer. In addition, if a woman presents with a mass in the pelvic area; CA 125 test is used to evaluate the mass and order further tests for management.
Many of you EndoSisters may have heard, or are following, the use of the biomarker CA-125 as a possible indicator of the presence of Endometriosis (read more here). I had my annual pap smear appointment this week and figured Id ask my doc to see if theyd run blood tests with my usual annual bloodwork.…
The Sysmex® CA-1500 System, with optional cap-piercing, is ideal for mid-volume laboratories requiring an easy to use analyzer capable of running clotting, chromogenic, and immunologic assays simultaneously. The system features multiple dilution analysis (MDA) for detecting inhibitors during factor assay analysis and accurate sample identification. By offering true 15-parameter random access testing and walk-away capability, the system offers both efficiency and flexibility for your laboratory.. ...
Sysmex® CA-1500 brzo analizira veliki broj uzoraka sa visokim nivoom preciznosti. Kompaktan, potpuno automatizovan sistem izvodi koagulometrijske, hromogene i imunološke testove ...
- Oregovomab in Combination with Chemotherapy Improves Clinical Outcome in Ovarian Cancer Patients TSX Venture: QPT EDMONTON , Nov.
CA 19-9 is a protein that may be elevated with some cancers, especially pancreatic cancer. A CA 19-9 test may be used to monitor treatment for pancreatic cancer.
Oganessian, Yu. Ts.; Utyonkov, V. K.; Lobanov, Yu. V.; Abdullin, F. Sh.; Polyakov, A. N.; Shirokovsky, I. V.; Tsyganov, Yu. S.; Mezentsev, A. N.; Iliev, S.; Subbotin, V. G.; Sukhov, A. M.; Subotic, K.; Ivanov, O. V.; Voinov, A. N.; Zagrebaev, V. I.; Moody, K. J.; Wild, J. F.; Stoyer, N. J.; Stoyer, M. A.; Lougheed, R. W.
JSC Isotope is an enterprise of Rosatom State Corporation working in the markets of isotope products, radiation devices, medical and general purpose equipment.
Infusions Ive interacted with a variety of professionals, and have decided to do some form of a fourth round, in order to get my CA-125 number down lower than the last reading of 38. It will be tested again on Tuesday morning, with other labs, before I see my gyn-onc, Dr. Guntupalli, and have infusions.…
Shop 1990 Ford Bronco Fuel Pumps, Regulators, Sending Units parts and get Free Shipping on orders over $99 at Speedway Motors, the Racing and Rodding Specialists. 1990 Ford Bronco Fuel Pumps, Regulators, Sending Units parts in-stock with same-day shipping.
TY - JOUR. T1 - Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. AU - Lu, Renquan. AU - Sun, Xinghui. AU - Xiao, Ran. AU - Zhou, Lei. AU - Gao, Xiang. AU - Guo, Lin. PY - 2012/3/9. Y1 - 2012/3/9. N2 - Human epididymis protein 4 (HE4) is a novel and specific biomarker for epithelial ovarian cancer (EOC). We previously demonstrated that serum HE4 levels were significantly elevated in the majority of EOC patients but not in subjects with benign disease or healthy controls. However, the precise mechanism of HE4 protein function is unknown. In this study, we generated HE4-overexpressing SKOV3 cells and found that stably transduced cells promoted cell adhesion and migration. Knockdown of HE4 expression was achieved by stable transfection of SKOV3 cells with a construct encoding a short hairpin DNA directed against the HE4 gene. Correspondingly, the proliferation and spreading ability of HE4-expressed cells were inhibited by HE4 suppression. ...
Book he4; human epididymis protein 4 lab test Online at best price with sample collection at home. Get detailed info about he4; human epididymis protein 4 lab test
Upper gastrointestinal neoplasia in the esophagus, stomach, and pancreas is associated with the formation of preneoplastic metaplasias. We have previously reported the up-regulation of human epididymis protein 4 (HE4) in all metaplasias in the stomach of humans and mice. We have now sought to evaluate the expression of HE4 in metaplasias/preneoplastic precursors and cancers of the human stomach, pancreas, and esophagus. Tissue microarrays for gastric cancers, pancreatic cancers, and esophageal adenocarcinoma were stained with antibodies against HE4. Immunostaining was quantified by digital imaging, and the results were evaluated to assess the expression in metaplasias, the expression in cancer pathological subtypes, and the effects of expression on survival in patients with cancer. In patients with gastric cancer from Korea, HE4 was detected in 74% of intestinal and 90% of diffuse cancers, whereas in a gastric cancer cohort from Johns Hopkins, HE4 was detected in 74% of intestinal-type and 92% ...
Diagnostic value of risk malignancy index (RMI) for detection of malignancies in clinically diagnosed ovarian masses and to evaluate the validity of individual constituent parameter of risk malignancy index
Background: Early diagnosis of ovarian cancer is essential for long term disease control and mortality reduction.This has been achieved using tumor markers like cancer antigen 125 (CA-125) which is elevated in malignant as wellas non-malignant conditions. This dilemma led to efforts towards development of newer markers like serum humanepididymis secretory protein E4 (HE4). Present study aimed to evaluate role of HE4 in diagnosing ovarian cancersand comparing it with CA-125. Methods: Serum samples from 67 patients with ovarian cancer, 42 with benignovarian masses and 26 healthy controls were collected preoperatively and tested for serum HE4 levels and CA-125levels. Diagnostic performance of both tumor markers (HE4/CA-125) to diagnose malignancy in ovarian masses wascalculated and compared to each other. Results: Mean CA-125 and HE4 levels were significantly higher in patientswith ovarian cancer than in those with benign disease (p|0.001) or healthy controls (p| 0.001). Serum HE4 levelssignificantly
Ovarian cancer is a common malignancy of the female reproductive system. Tumor markers serve as tools in the diagnosis of the disease. The aim of the present study was to determine the diagnostic value of sera levels of carbohydrate antigen-125 (CA-125), human epididymis protein 4 (HE4) as well as the area under the curve of the receiver operating characteristic (ROC) and the risk of ovarian malignancy algorithm (ROMA) index in ovarian cancer. The sera were measured using an electrochemiluminescence immunoassay on 158 individuals (64 patients with ovarian cancer, 64 with ovarian benign tumor and 30 healthy individuals) between September 2013 and May 2015. The results showed that levels of HE4 and CA‑125 in the sera of the ovarian benign tumor group as well as their ROMA index were significantly higher (P,0.05) than those of the ovarian benign tumor and control groups, regardless of pre‑ or postmenopausal status. However, the level of CA‑125 was significantly higher (P,0.05) in the ovarian ...
OBJECTIVE: The Risk of Malignancy Index (RMI) is a simple scoring system to standardize and improve the preoperative evaluation of adnexal masses. Since 1990, three versions of the RMI have been validated in different clinical studies. Recently, a fourth version of the RMI (RMI-4) was introduced that includes tumor size as an additional parameter. The aim of this study was to validate the ability of RMI-4 to discriminate between non-invasive lesions and invasive malignant adnexal masses, and to compare its performance with RMI-3. STUDY DESIGN: Women scheduled for surgery for an adnexal mass between 2005 and 2009 in 11 hospitals were included. Ultrasonographic characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI. The performances of RMI-3 and RMI-4 were assessed and statistically tested for differences. RESULTS: A total of 643 patients were included: 469 benign, 73 borderline and 101 malignant tumors. The RMI-3 had a sensitivity of ...
Metastatic Ovarian Cancer-Pipeline Review, H2 2015. Summary. Global Markets Directs, Metastatic Ovarian Cancer-Pipeline Review, H2 2015, provides an overview of the Metastatic Ovarian Cancers therapeutic pipeline.. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC ...
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. The patients were selected by systematic randomization sampling. Demographic, clinical, pathological, and therapeutic data were collected from patients hospital records. Statistical analyses were performed by Statistical Package for the Social Sciences version 16.0 software.Results: A total of 298 eligible patients enrolled in the study.
Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC).. Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values.. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3% and 59.4% for CA125, 84.6% and 94.2% for HE4, and 84.6% and 81.2% for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3% and 82.3% for CA125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, ...
Studies for a new heavy cruiser began in September 1939 similar to Wichita (CA-45), which would form the basis for this class, though her stability problem would have to be remedied. Machinery arrangement would be similar to that of the Cleveland (CL-55) class with the armored belt extending further foreward to protect against magnetic mines. Four ships were authorized on 1 July 1940; their construction was delayed due to the emphasis on light cruiser construction during the pre-war period. Sixteen more (CA-122 to 138) were ordered on 7 August 1942. Baltimore (CA-68) was the first to commission, in April 1943; Toledo (CA-133) was the last, in July 1946. CA-122 to 129 and 138 were re-ordered in late 1942 with design changes including boiler uptakes trunked into a single funnel, shortened superstructure, repositioned directors, and smaller hangar. This became the Oregon City (CA-122) class. Fourteen Baltimore class heavy cruisers were ulitimately built, with Norfolk (CA-137) being cancelled and ...
The CA125 blood test can be used to help diagnose or exclude ovarian cancer in combination with other tests and scans. Half of all women with early stage ovarian cancer do not have elevated CA125 levels, meaning it cannot be used as a reliable population screening test for ovarian cancer. It can only be used as a tool to assess symptoms suspected to be associated with ovarian cancer. It is more reliable as an indicator for ovarian cancer in postmenopausal women than in pre-menopausal women (Cancer Council Victoria). A CA-125 blood test can also be used to monitor progression of ovarian cancer, especially during treatment. After assessing baseline CA125 levels in a patient before undergoing treatment, results can be used to determine whether the treatment has been successful or not. A decrease in CA-125 levels during and after treatment can indicate that treatment has been successful, whereas increases may be evidence of a recurrence or further spread of the disease (Healthline).. ...
The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease. In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer. AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium. Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo. Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity. Most importantly, soluble human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity. These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of
BACKGROUND: There is no universal screening method for discrimination between benign and malignant adnexal masses yet. Various authors have tried tumor markers, imaging studies, cytology but no one yet is a definite method for screening of cancer ovary, for which a combined diagnostic modality has come to practice in form of RMI. With this background we conducted our study Evaluation of risk malignancy index and its diagnostic value in patients with adnexal masses. METHODS: The aim of the study was to determine the effectiveness of risk of malignancy index (RMI-3) in preoperative discrimination between benign and malignant masses and also to reveal the most suitable cut off value ...
An Unusual Association of Lung and Ovarian Malignancy in a Young Nonsmoker Female: 10.4018/ijudh.2012100104: Lung cancer in a 25-year-old nonsmoker female is extremely rare. Ovarian malignancy in this age group is also infrequent and if occurs, is usually of germ
Global Markets Directs, Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer pipeline
High levels of CA-125, the specific tumour marker for epithelial ovarian cancers are also found in inflammatory diseases of the pelvis. This case report of a 28 year-old woman with pathological CA-125 levels demonstrates the association between this finding and ascites caused by miliary tuberculosis. Tuberculostatic chemotherapy led to normalisation of the CA-125 levels within 8 weeks.
Serum levels of CA 15-3, an antigen expressed by human breast carcinoma cells, were measured in 58 ovarian cancer patients, 24 patients with benign ovarian tumor and 62 patients with benign gynecological conditions. Abnormally high serum CA 15-3 levels were found in 41 of 58 patients (71%) with ovarian cancer. The percentage of CA 15-3 positivity correlated with tumor stage. Elevated serum CA 15-3 levels were found in 5 of 24 patients (20%) with benign ovarian tumor. None of the patients with benign gynecological conditions had increased serum CA 15-3 levels. Serial measurements showed CA 15-3 concentrations to be correlated with the clinical behavior of disease in 21 of 25 patients (84%). CA 15-3 serum levels were also found to be correlated with findings on second look. These results suggest that CA 15-3 may represent a useful tumor marker in ovarian cancer.
Although some patients can be treated with surgery and chemotherapy, eventually most metastatic ovarian cancers become resistant to treatment. New options are needed for patients with advanced ovarian...
To Evaluate Pre-operative Serum Levels of Human Epididymis Protein (HE-4) and Cancer Antigen 125 (CA-125) in Women with Endometrial Cancer ...
We developed a prediction model using data from the women included in IOTA phases 1, 1b, and 2 (n=3506) and validated the model on data from the women included in phase 3 (n=2403).. The serum CA-125 tumour marker was not a mandatory variable, and measurements were missing in 31% of the patients. As described in detail in supplementary appendix A, we used multiple imputation to deal with missing values for CA-125.28 We created 100 imputations, resulting in 100 completed datasets.. We selected variables in two stages (see supplementary appendix B for details). Firstly, to avoid over-fitting we reduced the number of potential predictors to 10 based on subject matter knowledge29 30 and the stability of the predictors over centres.31 We selected four clinical variables-age (years), serum CA-125 level (U/mL), family history of ovarian cancer (yes/no), and type of centre (oncology centre v other hospitals), and six ultrasound variables-the maximum diameter of the lesion (mm), proportion of solid tissue ...
Thanks! ,From: Jim Kenzig; ,[email protected], ,Reply-To: [email protected] ,To: ,[email protected],, ,[email protected], ,Subject: [THIN] FW: CERT Advisory CA-2003-09 Buffer Overflow in Microsoft ,IIS 5.0 ,Date: Mon, 17 Mar 2003 19:05:52 -0500 , , ,If you are running IIS 5 patch now or suffer later. ,JK , ,-----Original Message----- ,From: CERT Advisory [mailto:[email protected]] ,Sent: Monday, March 17, 2003 2:07 PM ,To: [email protected] ,Subject: CERT Advisory CA-2003-09 Buffer Overflow in Microsoft IIS 5.0 , , , , ,-----BEGIN PGP SIGNED MESSAGE----- , ,CERT Advisory CA-2003-09 Buffer Overflow in Microsoft IIS 5.0 , , Original issue date: March 17, 2003 , Last revised: -- , Source: CERT/CC , , A complete revision history is at the end of this file. , ,Systems Affected , , * Systems running Microsoft Windows 2000 with IIS 5.0 enabled , ,Overview , , A buffer overflow vulnerability exists in Microsoft IIS 5.0 running on , Microsoft Windows 2000. ...
Fred Hutchinson Cancer Center researchers discovered that concentrations of the serum biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only…
Data Availability StatementAll data generated or analyzed in this scholarly research are contained in the present content. and impacting the cell routine. This development inhibitory effect due to WISP2 loss is because of the inhibition of phosphorylated extracellular signal-related kinase (p-ERK)1/2, aswell as CCAAT/enhancer-binding proteins (CEBP) and CEPB. Furthermore, WISP2 deletion also turned on the Yes-associated protein (YAP). Summary WISP2 deletion inhibits ovarian malignancy cell proliferation by influencing ERK signaling pathways. (CEBP) and CEBP. In addition, WISP2 deletion also triggered the Yes-associated protein (YAP). The current study exposed the potential of WISP2 as a factor capable of advertising ovarian malignancy cell proliferation and survival. Results WISP2 is definitely overexpressed in human being ovarian malignancy cells and cell lines WISP2 protein manifestation in human normal ovary cells and ovarian malignancy tissues was assessed via immunohistochemistry. WISP2 was ...
The importance of a raised serum CA 125 concentration for subsequent diagnosis of disease other than ovarian cancer has not been well documented to date. Of the 767 volunteers with a serum CA 125 concentration ,/=30 U/ml, only 49 developed cancer of the ovary or fallopian tube. We have previously reported that on serial sampling, serum CA 125 concentrations in most individuals with initially raised concentrations fall to ,30 U/ml.14 A minority of postmenopausal women, however, have persistently raised concentrations. Not all of these women will develop ovarian cancer, and the cause of the raised concentration in those who do not is currently unclear. The volunteers with one or more serum CA 125 concentrations ,/=30 U/ml are therefore being followed up closely to establish whether raised concentration is associated with subsequent development of benign or malignant disease other than an index cancer. There is no doubt that raised serum CA 125 concentration occurs in the advanced clinically ...
Cancer varies depending on the person, and this is also true when it comes to ovarian cancer. Learn more about what will come after diagnosis.
Researchers have developed a simple blood test that measures the bodys own immune response to improve diagnosis of ovarian cancer.
There are four stages of ovarian, fallopian tube, and peritoneal cancers. Learn how MSK doctors use this information to create a customized treatment plan.
When talking about my cancer diagnosis, Id say there are two parts to my story: The first part, when I fought for answers, and the second part,...
95% for ovarian malignancy. In patients who are not as carefully selected clinically, the utility of this test decreases, thus highlighting the need for careful clinical scrutiny. MUC16 (CA-125) has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms. One way that MUC16 helps the growth of tumors is by suppressing the response of natural killer cells, thereby protecting cancer cells from the immune response. Further evidence that MUC16 can protect tumor cells from the immune system is the discovery that the heavily glycosylated tandem repeat domain of MUC16 can bind to galectin-1 (an immunosuppressive protein). MUC16 is also thought to participate in cell-to-cell interactions that enable the metastasis of tumor cells. This is supported by evidence showing that MUC16 binds selectively to mesothelin, a glycoprotein normally expressed by the mesothelial cells of the peritoneum (the lining of the abdominal cavity). MUC16 and mesothelin ...
Anyone else find it odd that with only a week left until election day in CA-25 former President Obama is endorsing Christy Smith? President Obama was so on the fence about endorsing Christy Smith that he waited until CA-25 voters had been returning their ballots for THREE WEEKS before endorsing her?. What a vote of confidence!. ...
USS Boston (CA-69) 49 Star US Ensign - 4 July 1959 - 4 July 1960. USS Boston (CA-69), was a WWII - Available at 2020 June 6 Historic Flags of...
Table 3: Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts
Ovarian cancer is a silent killer; however, improvements in identification of women at high risk for ovarian cancer, as well as improved imaging techniques, have increased the likelihood of early dete... more
CA-800 APPLICATOR FEEDS AND CRIMPS REEL SMART™ CONTINUOUSLY MOLDED TERMINALS, DISCONNECTS AND SPLICES IN AUTOMATIC WIRE PROCESSING MACHINES AND BENCH PRESSES OPERATION MANUAL INTRODUCTION.................................................................. 1 SYSTEM SPECIFICATIONS ...................................................... 1 SAFETY PRACTICES............................................................. 1 WIRE PROCESSING MACHINE / PRESS COMPATIBILITY BY MANUFACTURER.................................... 2 APPLICATOR INSTALLATION PANDUIT CP-861 Bench Press .................................................. 3 APPLICATOR SETUP Die Insert Installation............................................................ Die Insert Changeover .......................................................... Crimp Shut Height Tolerance Test ............................................ REEL SMART™ System Reference Table ..................................... Applicator Loading ...
...BERKELEY CA- In a few seconds an origami artist can fold a sheet of ... Now computer models devised by Daniel Rokhsar and his colleag... The precise structure of biomolecules often reveals their fun...Protein shapes determine everything from the texture of hair and horn...,Model,Polymers,Reveal,New,Clues,to,Protein,Folding,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
What is the best time to start with CA-98? CA-98 capsules are effective in the fight against the aging of the body, But what is the right time to start taking CA-98 capsules? For which age group are the capsules the most suitable? CA-98 capsules are suitable for everyone, but when is the best time to start? Before […]. ...
A young advocate emphasizes the importance of communication between parents and their children about an ovarian cancer diagnosis.
(CA 125) a surface glycoprotein associated with mÑŒllerian epithelial tissue; elevated serum levels are often associated with epithelial ovarian carcinomas, particularly with nonmucinous tumors, but are also seen in some other malignant and…
This glycoprotein is a mucinous carbohydrate antigen product of the MUC1 gene expressed on various adenocarcinomas, especially breast. It is a high molecular weight (300-450 kDa) 1 polymor... ...
Unauthorized use of any materials presented here is prohibited. Copying or reproducing any elements from this page is not permitted. All prices, descriptions and availability subject to change ...
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Device connector for front wall, straight, shielded: Yes, SPEEDCON locking, M23, No. of pos.: 7, type of contact: Pin, Crimp connection, Axial seal, Central fastening M20 x 1.5
EXTON, Pa., Dec. 7, 2015 /PRNewswire/ -- Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With...
Tumor markers including alphafetoprotein (AFP), Beta Human Chorionic Gonadotropin (HCG), Carcinoembionic Antigen (CEA), CA 125 ... Scholler, Nathalie; Urban, Nicole (2007-12-01). "CA125 in Ovarian Cancer". Biomarkers in Medicine. 1 (4): 513-523. doi:10.2217/ ... ISBN 978-0-00-725092-9. Vickers, Andrew (1 March 2004). "Alternative Cancer Cures: "Unproven" or "Disproven"?". CA: A Cancer ... Prostate specific antigen (PSA). Treatment depends on the size and type of cancer. Breast cancer Treatment options include ...
CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumor markers are found in primary liver cancers ... Liver markers that can be increased with intrahepatic CCA are carcinoembryonic antigen (CEA), CA19-9, and CA-125. These are ... Jemal, A; Bray, F; Center, MM; Ferlay, J; Ward, E; Forman, D (Mar-Apr 2011). "Global cancer statistics". CA: A Cancer Journal ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 ( ...
Diagnosis of Pancreatic pseudocyst can be based on cyst fluid analysis: Carcinoembryonic antigen (CEA) and CA-125 (low in ...
There is no specific marker for immature teratomas, but carcinoembryonic antigen (CEA), CA-125, CA19-9, or AFP can sometimes ... CA-125 levels in premenopausal people over 200 U/mL may indicate ovarian cancer, as may any elevation in CA-125 above 35 U/mL ... CA-125 levels are not accurate in early stage ovarian cancer, as fully half of stage I ovarian cancer patients have a normal CA ... A blood test for a marker molecule called CA-125 is useful in differential diagnosis and in follow up of the disease, but it by ...
... is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly ... antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is ... 3009.3CA125. "Medical News: ESGO: Anti-CA125 Fails to Slow Ovarian Cancer - in Meeting Coverage, ESGO from". MedPage Today. ... Abagovomab does not bind directly to CA-125, but it works as a "surrogate" ...
Vickers, Andrew (1 March 2004). "Alternative Cancer Cures: "Unproven" or "Disproven"?". CA: A Cancer Journal for Clinicians. 54 ... Tumor markers including alphafetoprotein (AFP),[47] Beta Human Chorionic Gonadotropin (HCG),[47] Carcinoembionic Antigen (CEA), ... "CA125 in Ovarian Cancer". Biomarkers in Medicine. 1 (4): 513-523. doi:10.2217/17520363.1.4.513. ISSN 1752-0363. PMC 2872496 ...
CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are found in primary liver ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 ( ...
June 2008). "Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific ... Böttiger LE, Svedberg CA (1967). "Normal erythrocyte sedimentation rate and age". Br Med J. 2 (5544): 85-87. doi:10.1136/bmj. ... Carcinoembryonic Antigen(CEA) at MedicineNet Luboldt, Hans-Joachim; Schindler, Joachim F.; Rübben, Herbert (2007). "Age- ... R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. ...
When performing this procedure at ~70 K (i.e. with liquid nitrogen), para-hydrogen is enriched from 25% to ca. 50%. When ... Prostate-Specific Antigen) and has been contributing to prostate cancer. There are a lot of biomarkers are considering as being ... Proton NMR signals with ca. 10,000-fold increased intensity can be obtained compared to NMR signals of the same organic ... CA-125), Human Immunodeficiency Virus -Ribonucleic Acid (HIV RNA), B-type Natriuretic Peptide (BNP).27and Lymphoma cell (Ramos ...
Examples: Prostate-specific antigen, and CA-125 Antibodies to cancer antigens Examples: Merkel cell polyomavirus DNA Examples: ... Bantis, A; Grammaticos, P (Sep-Dec 2012). "Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate ... Gupta, Digant; Lis, Christopher G. (2009-10-09). "Role of CA125 in predicting ovarian cancer survival - a review of the ... CA-125 (Ovarian Cancer), CA19.9 (Pancreatic Cancer), CEA (Colorectal Cancer), EGFR (Non-small-cell lung carcinoma), HER-2 ( ...
... ca-15-3 antigen MeSH D23. - ca-19-9 antigen MeSH D23. - ca-125 antigen MeSH D23.050.285.062 - ... ca-15-3 antigen MeSH D23.050.550.325.119 - ca-19-9 antigen MeSH D23.050.550.325.225 - ca-125 antigen MeSH D23.050.550.395 - ... ca-15-3 antigen MeSH D23.101.840.075.119 - ca-19-9 antigen MeSH D23.101.840.075.225 - ca-125 antigen MeSH D23.101.840.100 - ... antigens, cd15 MeSH D23.101.100.900.131 - antigens, cd31 MeSH D23.101.100.920 - antigens, ly MeSH D23.101.100.930 - antigens, ...
McLemore moved to the University of California, San Francisco for her graduate studies, where she studied CA-125; an antigen ... McLemore, Monica Rose; University of California, San Francisco; Nursing; University of California, San Francisco (2010). An ... PTBi-California looks to mitigate for the disproportionate impact that preterm births have on already marginalised communities ... McLemore was part of the preterm birth initiative (PTBi-California), which looks to understand why preterm births mainly occur ...
Yin BW, Lloyd KO (Jul 2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". The ... Yin BW, Dnistrian A, Lloyd KO (Apr 2002). "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". International ... Boivin M, Lane D, Piché A, Rancourt C (Dec 2009). "CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian ... Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CA-125 at Lab Tests Online CA-125 analyte ...
... also known as CA125, is an abbreviation for cancer antigen 125 125 High Street is a 30-floor high-rise in Boston 125th ( ... California USNS Mission San Jose (T-AO-125), a US Navy fleet oiler during World War II USS Tide (AM-125), a US Navy minesweeper ... 125 is the cube of 5. It can be expressed as a sum of two squares in two different ways, 125 = 10² + 5² = 11² + 2². 125 and 126 ... 125 is also: The year AD 125 or 125 BC 125 AH is a year in the Islamic calendar that corresponds to 742 - 743 CE 125 Liberatrix ...
... which enables the immune system to recognize antigens. 1982: Dana-Farber researchers develop and apply the CA-125 blood test ...
Immunol., 22, (1998), p. 379-385 Weill, J.-C. and Reynaud, C.-A., « DNA polymerases in adaptive immunity », Nature Reviews ... Hypermutation generating the sheep Ig repertoire is an antigen-independent process », Cell, 80, (1995), p. 115-125 Weill J.-C. ... C.-A, « Human marginal zone B cells. », Annu. Rev. Immunol., 27, (2009), p. 267-285 "Google Scholar". "Académie des sciences ... and Reynaud, C.-A., « GALT versus bone marrow models of B cell ontogeny », Develop. Comp. ...
CA 19-9, CA 72-4 Liver: CEA, AFP Oesophagus: CEA, Cyfra 21-1 Thyroid: CEA, NSE Lung: CEA, CA 19-9, CA 125, NSE, Cyfra 21-1 ( ... Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (January 2008). "Value of cancer antigen 125 for ... CA 15-3, Cyfra 21-1 Ovary: CEA, CA 19-9, CA 125, AFP, BHCG Uterine: CEA, CA 19-9, CA 125, Cyfra 21-1, SCC Prostate: PSA, FPSA ... "Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012". > ca-19-9 Retrieved November 2011 ...
St Hill CA (June 2011). "Interactions between endothelial selectins and cancer cells regulate metastasis". Frontiers in ... One of the reported ligands for E-selectin is the sialylated Lewis X antigen (SLex). Eosinophils, like neutrophils, use ... Bochner BS, Sterbinsky SA, Bickel CA, Werfel S, Wein M, Newman W (January 1994). "Differences between human eosinophils and ... Wein M, Sterbinsky SA, Bickel CA, Schleimer RP, Bochner BS (March 1995). "Comparison of human eosinophil and neutrophil ligands ...
Takayama TK, Carter CA, Deng T (2001). "Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human ... 276 (1): 125-33. doi:10.1006/bbrc.2000.3448. PMID 11006094. Gan L, Lee I, Smith R, et al. (2001). "Sequencing and expression ...
"TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02. Scott AM, Wolchok JD, Old LJ (March ... tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 ... is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes ... Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in ...
Berkeley, Calif.: University of California Press. ISBN 0-520-08096-3. .. CS1 maint: extra text: authors list (link). ... Prostate-specific antigen (PSA) - this is an enzyme (a chemical that speeds up chemical reactions) which causes the semen to ... San Francisco, Calif.: HarperSanFrancisco. p. 576. ISBN 0-06-250923-3. .. *↑ Gary J. Clyman. "Sexual Kung Fu [ch. 8]". The Chi ... 132 (2): 123-125.. (In French.) *↑ S. Weidinger; J. Ring, F.M. Köhn (2005). "IgE-mediated Allergy against Human Seminal Plasma" ...
... small clusters of microglial cells with enhanced major histocompatibility complex class II antigen, CD45 and CD68 antigen ... Rus H, Pardo CA, Hu L, et al. (August 2005). "The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory ... Haegele KF, Stueckle CA, Malin JP, Sindern E (February 2007). "Increase of CD8+ T-effector memory cells in peripheral blood of ... Given CA, Stevens BS, Lee C (1 January 2004). "The MRI appearance of tumefactive demyelinating lesions". AJR Am J Roentgenol. ...
Jacobson CA, Ritz J (November 2011). "Time to put the CAR-T before the horse". Blood. 118 (18): 4761-2. doi:10.1182/blood-2011- ... Identification of good antigens has been challenging: such antigens must be highly expressed on the majority of cancer cells, ... After an antigen is bound to the external antigen recognition domain, CAR receptors cluster together and transmit an activation ... T cells are genetically engineered to express chimeric antigen receptors specifically directed toward antigens on a patient's ...
Harven, E.; Soligo, D.; Christensen, H. (1990). "Double labelling of cell surface antigens with colloidal gold markers". The ... De Harven, E. (1977). "Electron Microscopy: Remarks on 40 Years Of Ultrastructural Explorations". CA: A Cancer Journal for ... where he researched the marking of antigens on the surface of lymphocytes. As former President of the Microscopy Society of ... p. 125. ISBN 978-1-4419-0305-1.. Kalichman, Seth C. (2009). Denying AIDS: conspiracy theories, pseudoscience, and human tragedy ...
... histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is ... Gao GF, Willcox BE, Wyer JR, Boulter JM, O'Callaghan CA, Maenaka K, Stuart DI, Jones EY, Van Der Merwe PA, Bell JI, Jakobsen BK ... McIntire RH, Hunt JS (2005). "Antigen presenting cells and HLA-G--a review". Placenta. 26 Suppl A: S104-9. doi:10.1016/j. ... "Entrez Gene: HLA-G HLA-G histocompatibility antigen, class I, G". Castelli, Erick C.; Mendes-Junior, Celso T.; Veiga-Castelli, ...
Janeway CA, Travers P, Walport M, Shlomchik MJ (2001). Immunobiology (5th ed.). New York: Garland Science. p. 104. ISBN 0-8153- ... For example, IgM is said to have low affinity but high avidity because it has 10 weak binding sites for antigen as opposed to ... Calculation of binding affinity for bimolecular reaction (1 antibody binding site per 1 antigen): [ Ab ] + [ Ag ] ↽ − − ⇀ [ ... is the antigen concentration, either in free ([Ab],[Ag]) or bound ([AbAg]) state. calculation of association constant (or ...
CA-125 levels appear to fall during endometriosis treatment, but it has not shown a correlation with disease response. Another ... Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS (October 2016). "Diagnostic accuracy of cancer antigen 125 for ... The one biomarker that has been in use over the last 20 years is CA-125. A 2016 review found that this biomarker was present in ... Scutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, Greco P, Nappi L (2017). "Oxidative Stress and ...
Lowry F (2008-05-15). "Live Listeria Vaccine Proves Safe Against End-Stage Cervical Ca in Human Trial". Ob. Gyn. News. 43 (10 ... Chu NJ, Armstrong TD, Jaffee EM (April 2015). "Nonviral oncogenic antigens and the inflammatory signals driving early cancer ... 10 (1): 125-59. doi:10.1128/CMR.10.1.125. PMC 172946. PMID 8993861. "103051F-EN-RevC" (PDF). Hologic. Archived from the ...
San Diego, CA: Academic Press. pp. 453-67. ISBN 978-0123878373. Vanwijk, M; Vanbavel, E; Sturk, A; Nieuwland, R (2003). " ... CD154 knockout mice are incapable of producing IgG, IgE, or IgA as a response to antigens. Microvesicles can also transfer ... This mechanism of action can be used in processes such as antigen presentation, where MHC molecules on the surface of ... For example, those released from antigen-presenting cells (APCs), such as B cells and dendritic cells, are enriched in proteins ...
"Ca. 61 (2): 69-90. doi:10.3322/caac.20107. PMID 21296855.. *^ Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et ... Androgeni receptor pomaže ćelijama raka da prežive.[74] Prostatski specifični membranski antigen (PSMA) podstiče razvoj raka ... "CA: A Cancer Journal for Clinicians. 68 (6): 394-424. doi:10.3322/caac.21492. PMID 30207593.. ... Filson CP, Marks LS, Litwin MS (8. 5. 2015). "Expectant management for men with early stage prostate cancer". Ca. 65 (4): 265- ...
Journal of the California Dental Association. 41 (4): 263-8. PMID 23705242. Yamada T, Alpers DH, et al. (2009). Textbook of ... in persons with blood group O and in non-secretors of blood group antigens in saliva. Increased rates of Candida carriage are ... CA: A Cancer Journal for Clinicians. 62 (6): 400-22. doi:10.3322/caac.21157. PMID 22972543. Odell EW (Editor) (2010). Clinical ... 5 (2): 125-57. doi:10.1177/10454411940050020101. PMID 7858080. Li, X; Lei, L; Tan, D; Jiang, L; Zeng, X; Dan, H; Liao, G; Chen ...
OspA antigens, shed by live Borrelia bacteria into urine, are a promising technique being studied.[117] The use of nanotrap ... " 4 July 2012. Archived from the original on 27 December 2012. Retrieved 15 December 2012.. ... Walsh CA, Mayer EW, Baxi LV (January 2007). "Lyme disease in pregnancy: case report and review of the literature". Obstetrical ... " Archived from the original on 3 January 2013. Retrieved 15 December 2012.. ...
Peptide antigens are displayed by the major histocompatibility complex class I (MHC) proteins on the surface of antigen- ... Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky SL, Darnell J (2004). "3". Molecular cell biology (5th ... Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E, Marambaud P (July 2000). "Role of the proteasome in Alzheimer's ... Zhang M, Coffino P (March 2004). "Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome ...
I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... CA 15-3. *erbB-2 receptor. *erbB-3 receptor. *Cathepsin D. *Ca 27-29 ...
1 - antigen; 2 - IgE antibody; 3 - FcεRI receptor; 4 - preformed mediators (histamine, proteases, chemokines, heparin); 5 - ... Marra F, Lynd L, Coombes M, Richardson K, Legal M, Fitzgerald JM, Marra CA (March 2006). "Does antibiotic exposure during ...
1 - antigen. 2 - IgE antibody. 3 - FcεRI receptor. 4 - preformed mediators (histamine, proteases, chemokines, heparin). 5 - ... Cuello-Garcia CA, Brożek JL, Fiocchi A, et al. (2015). "Probiotics for the prevention of allergy: A systematic review and meta- ... Other widely promoted tests such as the antigen leukocyte cellular antibody test and the food allergy profile are considered ... 125] For infants, supplementing their diet with oils high in PUFAs did not affect the risks of food allergies, eczema or asthma ...
Cooney CA, Dave AA, Wolff GL (August 2002). "Maternal methyl supplements in mice affect epigenetic variation and DNA ... has a 10-40-fold preference for hemimethylated DNA and interacts with the proliferating cell nuclear antigen (PCNA).[51] ... Dupont C, Armant DR, Brenner CA (September 2009). "Epigenetics: definition, mechanisms and clinical perspective". Seminars in ... 125] Congenital genetic disease is well understood and it is clear that epigenetics can play a role, for example, in the case ...
CDCR), California Department of Corrections and Rehabilitation. "State of California Inmate Locator". ... and when Judge Huff did order retesting she limited the testing to hairs that were proven not to have Antigen roots ( ... Denial of clemency by California Governor Schwarzenegger[edit]. On January 30, 2004, the office of Governor of California ... California Supreme Court upholds stay on execution[edit]. This section of a biography of a living person does not include any ...
Evidence that the antigens of the Yt blood group system are located on human erythrocyte acetylcholinesterase.. Blood. 1992, 80 ... Soreq H, Ben-Aziz R, Prody CA; 等. Molecular cloning and construction of the coding region for human acetylcholinesterase ... Lapidot-Lifson Y, Prody CA, Ginzberg D; 等. Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in ... 1986, 25 (1): 125-30. PMID 3954986. doi:10.1021/bi00349a019.. *. Gaston SM, Marchase RB, Jakoi ER. Brain ligatin: a membrane ...
doi:10.3322/CA.2007.0010. PMID 18287387.. *^ "Cancer Stat Facts: Prostate Cancer". National Cancer Institute. Archived from the ... Prostate specific membrane antigen is a transmembrane carboxypeptidase and exhibits folate hydrolase activity.[75] This protein ... Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). "Global cancer statistics". CA - A Cancer Journal for Clinicians ... Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (March 2008). "Cancer Statistics, 2008". CA Cancer J Clin. 58 (2): 71 ...
Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, ... Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated ... 28 (1): 116-125. doi:10.1111/sms.12901. PMID 28449327.. *^ Sauce D, Larsen M, Curnow SJ, Leese AM, Moss PA, Hislop AD, Salmon M ... "Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens". Nature. 471 (7337): 220-4. ...
" Retrieved 6 December 2017.. *^ Nelson Essentials of Pediatrics By Karen Marcdante, Robert M. Kliegman, Richard E ... Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors" ... TdT is a protein expressed early in the development of pre-T and pre-B cells, whereas CALLA is an antigen found in 80% of ALL ... Chimeric antigen receptors (CARs) have been developed as a promising immunotherapy for ALL. This technology uses a single chain ...
Saunders WS, Cooke CA, Earnshaw WC (1991). "Compartmentalization within the nucleus: discovery of a novel subnuclear region". ... Oct1 and PIKA antigens associates with specific chromosomes early in the cell cycle". EMBO J. 17 (6): 1768-1778. doi:10.1093/ ... Moreno F, Ahuatzi D, Riera A, Palomino CA, Herrero P. (2005). "Glucose sensing through the Hxk2-dependent signalling pathway". ... 125 (125): 127-137. doi:10.1007/s00418-005-0046-4.. *↑ ೨೬.೦ ೨೬.೧ Lamond, Angus I. "Nuclear substructure and dynamics". Current ...
Berkeley: University of California Press. ISBN 978-0-520-24220-3. .. *. Mack T (2003). "A different view of smallpox and ... which measured Variola virus-specific immunoglobulin and antigen were also developed to assist in the diagnosis of infection.[ ... "University of California Press. Archived from the original on 7 September 2008. Retrieved 22 February 2009.. ... Berkeley and Los Angeles: University of California Press. ISBN 978-0-520-23732-2. .. ...
E. Crowley, CA. McDevitt, R. Callaghan (2009). Multidrug Resistance in Cancer. Generating Inhibitors of P-Glycoprotein: Where ... The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells ... They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted ... Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; ...
Herter, CA (1908). On infantilism from chronic intestinal infection; characterized by the overgrowth and persistence of flora ... HLA-DQ is part of the MHC class II antigen-presenting receptor (also called the human leukocyte antigen) system and ... Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Ebell M, Epling JW, Herzstein J, Kemper AR, Krist ... Mein CA, Mirza MM, Mistry V, Mora B, Morley KI, Mulder CJ, Murray JA, Núñez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, ...
Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, ... The increased expression of miR-181a in mature T cells increases susceptibility to peptide antigens, while inhibiting the ... suggesting that miR-181a acts as an antigen intrinsic sensitivity "rheostat" during the development of T cells. It has been ... 40 (1): 125. doi:10.1111/j.1365-2052.2008.01780.x. PMID 18945293. Jin W, Grant JR, Stothard P, Moore SS, Guan LL (September ...
DOI: 10.1097/01.TP.0000106470.07410.CA. PMID: 14726768. *↑ R.J. Robb, K.E. Lineburg, R.D. Kuns, Y.A. Wilson i inni. ... Antigen-specific peripheral shaping of the natural regulatory T cell population. „J Exp Med". 205 (13), s. 3105-3117, grudzień ... De novo production of antigen-specific suppressor cells in vivo. „Nat Protoc". 1 (2), s. 653-661, 2006. PMID: 17802642. ... Human regulatory T cells rapidly suppress T cell receptor-induced Ca(2+), NF-κB, and NFAT signaling in conventional T cells. „ ...
Isaac A. Adler, A.M., M.D". Ca. 30 (5): 295-301. doi:10.3322/canjclin.30.5.295. PMID 6773624.. ... Carcinoembryonic antigen (CEA) is a marker found in several forms of cancer. Levels in exclusive hookah smokers were lower ... Thun MJ, Day-Lally CA, Calle EE, Flanders WD, Heath CW (September 1995). "Excess mortality among cigarette smokers: changes in ... Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S (November 2006). "Smoking and inflammatory bowel disease: a meta-analysis ...
Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection., 110 ... Janeway CA Jr, Travers P, Walport M, et al., Generation of lymphocytes in bone marrow and thymus, "Immunobiology: The Immune ... Janeway CA Jr, Travers P, Walport M, et al., Generation of lymphocytes in bone marrow and thymus, "Immunobiology: The Immune ... Ana C. Anderson ja Vijay K. Kuchroo, Expression of Self-antigen in the Thymus A Little Goes a Long Way, 1. detsember 2003 // ...
" Archived from the original on 26 February 2012. Retrieved 27 February 2012.. ... and that they have low levels of T cell-independent antigens.[17][19] United Network for Organ Sharing (UNOS) regulations allow ... the period under which a recipient may undergo ABOi transplantation may be prolonged by exposure to nonself A and B antigens.[ ... 125][118] The first partial success was achieved on 3 December 1967, when Christiaan Barnard of Cape Town, South Africa, ...
嵌合抗原受體T細胞免疫療法(Chimeric Antigen Receptor T-Cell Immunotherapy)乃是先取得患者自身的T細胞後,在體外以基因工程的技術,使T細胞具有辨識癌細胞的能力後,再回輸到患者身上。被改造後的T細胞即稱為嵌合抗 ... California Environmental Protection Agency. Tobacco Control. 1997, 6 (4): 346-53. PMC 1759599. PMID 9583639. doi:10.1136/tc.6.4 ... Powell CA, Halmos B, Nana-Sinkam SP. Update in lung cancer and mesothelioma 2012. American
Ca 90 % av alle personer med anoreksi er kvinner.[184] I den norske befolkningen forekommer anoreksi i ca. 20 tilfeller per 100 ... Serodiagnosis of Lyme disease by ELISA using Borrelia burgdorferi flagellum antigen]». Rinsho Byori (Japanese). 39 (8): 891-4. ... Blant yngre kvinner er antallet nye tilfeller ca. 50 per 100 000 per år. Totalt i den norske befolkningen regner vi med at 1-2 ... 13 (1): 125-8. PMID 8477271. doi:10.1002/1098-108X(199301)13:1,125::AID-EAT2260130115,3.0.CO;2-4.. CS1-vedlikehold: Flere navn ...
It has been suggested that the presence of antibodies to Streptococcus bovis/gallolyticus antigens or the antigens themselves ... Ca. 68 (4): 250-281. doi:10.3322/caac.21457. PMID 29846947.. ... Carcinoembryonic antigen blood level measurements follow the ... Palliative care is recommended for any person who has advanced colon cancer or who has significant symptoms.[125][126] ... 125-126 In 2018 the National Cancer Institute stated that "There is no reliable evidence that a diet started in adulthood that ...
... xeralmente Mn2+ e Ca2+). Ten unha simetría D2.[1] A súa estrutura terciaria xa foi determinada,[7] e as bases moleculares da ... "Concanavalin A receptors, immunoglobulins, and theta antigen of the lymphocyte surface. Interactions with concanavalin A and ... "The Journal of Biological Chemistry 125 (1): 45-48.. ; Sumner, J. B.; Gralen, N.; Eriksson-Quensel, I.-B. (1938). "The ...
... oleh pengenal antigen.[59] Respons imun adaptif bersifat spesifik terhadap antigen tertentu dan membutuhkan pengenalan antigen ... Winstanley C, Hart CA (2001). "Type III secretion systems and pathogenicity islands". J Med Microbiol. 50 (2): 116-26. PMID ... Oleh sistem imun, antigen tersebut dianggap sebagai antigen asing dan keberadaannya mendorong sel imun untuk menyerang sel ... Sel T pembantu mengekspresikan reseptor sel T yang mengenali antigen terikat pada molekul MHC kelas II. MHC:antigen juga ...
California, The State Bar of. "Sharon M Huddle #105101 - Attorney Search". Retrieved August 13, 2018.. ... Non-secretor: Sperm does not contain blood-group antigens.[127]. *Physically agile and capable of sprinting, bicycling, and ... Huddle went to college in Fresno, California. Afterwards, she attended law school in Sacramento, California. She became an ... 2 million supporting California Proposition 69 authorizing DNA collection from all California felons and certain other ...
antigen processing and presentation of exogenous peptide antigen via MHC class II. • proteolysis. • neutrophil degranulation. ... Mueller CA, Kalbacher H (March 2006). "Cathepsin D is present in human eccrine sweat and involved in the postsecretory ... brain antigen processing and regulation of programmed cell death.[17][18][19][20] ...
"First Antigen Rapid Test for Ebola through Emergency Assessment and Eligible for Procurement". World Health Organization. ... " CBC/Radio-Canada. 12 September 2007. Archived from the original on 19 November 2014.. ... In 2015 a rapid antigen test which gives results in 15 minutes was approved for use by WHO. It is able to confirm Ebola in 92% ... 125] Quarantine, also known as enforced isolation, is usually effective in decreasing spread.[126][127] Governments often ...
惡性瘧原蟲帶來的高死亡率和罹病率,造成人類近代史上最大的演化壓力,造成某些對瘧疾有抵抗力的基因篩選出來。不幸地,這些基因通常也會造成紅血球發育不良,導致鐮刀型紅血球疾病、海洋性貧血、蠶豆症、或紅血球表面達菲抗原(英语:Duffy antigens)缺乏[ ... Guerra CA, Hay SI, Lucioparedes LS, Gikandi PW
Sometimes CA-125 may be ordered to help detect early ovarian cancer in women at high risk (e.g., BRCA mutation) or to help ... CA-125) is a tumor marker primarily used to monitor treatment of ovarian cancer and to detect whether cancer has come back ... If CA-125 levels rise or stay the same, then the cancer may not be responding to therapy. High CA-125 levels after treatment is ... CA-125 is also used to detect whether cancer has come back after treatment is complete. A series of CA-125 tests that shows ...
The CA-125 blood test can spot proteins made by ovarian cancer, but it doesnt always mean you have cancer. WebMD explains why ... The CA-125 test also may be done if you have a lump in your pelvic area. It will help your doctor figure out the cause of the ... Cancer antigen 125 test Your doctor may order a CA-125 test if youre about to start treatment for ovarian cancer. The test ... The CA-125 test looks for certain proteins in your blood. Ovarian cancer can be the reason for these proteins, but other ...
CA125) is a protein produced by a variety of cells, particularly ovarian cancer cells. It is found in trace amounts in the ... How a CA125 test is done. A CA125 test is a blood test that measures the amount of CA125 protein in the blood. A sample of ... Why a CA125 test is done. A CA125 test may be done: * if the doctor suspects there may be cancer ... CA125). Cancer antigen 125 (CA125) is a protein found on most ovarian cancer cells that is secreted into the blood stream and ...
Read our Cancer Antigen 125 (CA-125) encyclopedia resources online. ... CA-125) test that can help show if some types of cancer are present. Covers its use to check how well treatment for ovarian ... Cancer Antigen 125 (CA-125). Skip to the navigation Test Overview. Cancer antigen 125 (CA-125) is a protein found on the ... CA-125 is used as a tumor marker, which means the test can help show if some types of cancer are present. Most often, the CA- ...
CA-125) test that can help show if some types of cancer are present. Covers its use to check how well treatment for ovarian ... Cancer antigen 125 (CA-125) is a protein found on the surface of many ovarian cancer cells. It also can be found in other ... CA-125 is used as a tumor marker, which means the test can help show if some types of cancer are present. Most often, the CA- ... High values of CA-125 in a woman who has been treated for ovarian cancer may mean that the cancer has returned. Often the high ...
CA-125) test that can help show if some types of cancer are present. Covers its use to check how well treatment for ovarian ... Cancer Antigen 125 (CA-125) Test. Test Overview. Cancer antigen 125 (CA-125) is a protein found on the surface of many ovarian ... CA-125 is used as a tumor marker, which means the test can help show if some types of cancer are present. Most often, the CA- ... High levels of CA-125 are a strong sign that the cancer started in the ovary. But other types of cancer can increase CA-125 ...
CA-125) tumor marker for Ovarian and other malignant cancers for research and in vitro diagnostic manufacturing - Inquire for ... Home / Antigens / Enzymes / Antigens / Standards / Controls / Proteins / Cancer Antigen 125 (ca-125) ... CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular ... Low Cross Contamination: CA 15-3, CEA, CA 19-9. Formulation. Solution in phosphate buffered saline pH 7.4 with 3% sucrose and ...
CA-125) monoclonal antibody for research, life science and manufacturing uses - Inquire for more details! ... Antigens , Enzymes. We produce and manufacture high quality antigens, proteins and enzymes for a wide range of life science ... Capture Ab: 151-29 - anti-Human CA-125 Monoclonal Antibody. Detection Ab: 151-30 - anti-Human CA-125 Monoclonal Antibody. ...
Colorimetric Assay for Quantitative measurement of human CA-125 in serum, plasma, urine & cell culture supernatants. Detection ... Milpitas, CA 95035.. Tel: 408.493.1800. Fax: 408.493.1801. Toll Free: 800.891.9699 (US Only). Tech Support: [email protected]. ... CA-125 Ab-coated Microplate, 96 wells. • Wash Buffer (20x). • Human CA-125 Standard. • Assay Diluent (5x). • Detection Antibody ... The minimum detectable dose of CA-125 is typically less than 0.6 U/ml. Detection Range: 0.6 U/ml - 400 U/ml. The intra-Assay ...
... cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in ... CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease. Mikkelsen, Gustav; Åsberg, Arne; Hultström, Maria ... Estimated reference limits for plasma CA 125, CA 19-9 and CEA were approximately the same as for healthy populations. Serum ... Reference limits for chromogranin A, CYFRA 21-1, CA 125, ...
A randomised trial in relapsed ovarian cancer, early treatment based on Cancer Antigen (CA) 125 levels alone versus delayed ... A randomised trial in relapsed ovarian cancer, early treatment based on Cancer Antigen (CA) 125 levels alone versus delayed ... 2. In complete remission with a normal CA125 since first-line platinum containing chemotherapy. 3. A normal CA125 result within ... Following a raised CA125 result patients are randomised to receive either delayed treatment until patient shows clinical signs ...
Mouse Carbohydrate Antigen 125 (CA125) ELISA Kit-P06731.3 (MBS264824) product datasheet at MyBioSource, ELISA Kits ... carcinoembryonic antigen-related cell adhesion molecule 5; meconium antigen 100 UniProt Protein Name Carcinoembryonic antigen- ... The ELISA analytical biochemical technique of the MBS264824 kit is based on CA125 antibody-CA125 antigen interactions ( ... CA125 elisa kit :: Mouse Carbohydrate Antigen 125 (CA125) ELISA Kit. Catalog #. MBS264824 .mycenter { display: block; margin- ...
Bovine Ovarian Cancer Marker/Carbohydrate Antigen 125 ELISA Kit (MBS023627) product datasheet at MyBioSource, ELISA Kits ... The ELISA analytical biochemical technique of the MBS023627 kit is based on OCM-CA125 antibody-OCM-CA125 antigen interactions ( ... OCM-CA125 Bovine OCM-CA125. LOG IN MY ACCOUNT CART CONTENTS CHECKOUT ... OCM-CA125 elisa kit :: Bovine Ovarian Cancer Marker/Carbohydrate Antigen 125 ELISA Kit. ...
Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... The specificity of CA 125 at upper limits of 30 and 50 U/mL was increased from 97.0 and 99.5%, respectively, to 98.9 and 99.9% ...
CA 125 Antigen. CA 125 Antigen is a heterogonous glycoprotein. It can be detected in ovarian cancer. Moderately elevated values ... CA 125 determination is used mainly for diagnosis and monitoring of ovarian cancer. ...
There are two common oncofetal antigens, alphafetoprotein (AFP) and carcinoembryonic antigen (CEA). Carcinoembryonic antigen CA ... Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are ... Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are ... Cancer antigen 15-3 (CA 15-3) CA 15-3 is produced by cells in the breast and increased levels can be associated with breast ...
The antigen CA 125,with a molecular weight of 220kD glycoprotein is present in the epithelium of the following organs: ovary, ... CA 125 hasa major diagnosis relevance in ovarian serous cancer; it can also be used as a secondary marker in pancreatic cancer ... CA 125 cannot be used for ovarian cancer screening in the general population because of its lack of sensitivity for early stage ... In patients with a family history of breast or ovarian cancer this marker - CA 125should be evaluated every 6 months, along ...
TEST : Access Ovarian Cancer Test - OV Monitor (CA 125 antigen) Access OV Monitor aids in the management of ovarian cancer and ... CA 125 antigen levels are most consistently elevated in patients with ovarian cancer. The assay produces first results in 20 ... ACCESS Tumor marker - OV monitor (CA 125 Antigen). BECKMAN - Tumor marker TEST Access Ovarian Cancer Test - OV Monitor CA 125 ... such as transvaginal ultrasonography and a mathematical algorithm that analyzes rates of change of CA 125. The test is ...
CA125 Enzyme Immunoassay. INTENDED USE. For the quantitative determination of the Cancer Antigen CA125 concentration in human ... CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular ... Enzyme Immunoassay for the Quantitative Determination of Ovarian Cancer Antigen CA125 in Human Serum. FOR IN VITRO DIAGNOSTIC ... CA125 is an antigen present on 80 percent of nonmucinous ovarian carcinomas. It is defined by a monoclonal antibody ( OC125 ) ...
CA 27.29 - Cancer Antigen. 140293 - Quantitative measurement of Cancer Antigen 27.29. This testing is often done to help manage ... Carbohydrate Antigen 19-9 (CA 19-9). 002261 - The CA 19-9 is used to monitor gastrointestinal, pancreatic, liver and colorectal ... Cancer Antigen (CA) 15-3. 143404 - Quantitative measurement of cancer antigen 15-3. ... Cancer Antigen (CA) 125. 002303 - A CA 125 test measures the amount of the protein CA 125 (cancer antigen 125) in your blood. A ...
Mouse CA125(Carbohydrate Antigen 125) ELISA Kit. Mouse CA125(Carbohydrate Antigen 125) ELISA Kit ... Description: A sandwich CLIA kit for quantitative measurement of Human CA125 (Carbohydrate Antigen 125) in samples from Serum, ... Description: A sandwich ELISA kit for quantitative measurement of Human CA125 (Carbohydrate Antigen 125) in samples from Serum ... CA125 encodes a protein that is a member of the mucin family. Mucins are high molecular weight, O-glycosylated proteins that ...
In addition, if a woman presents with a mass in the pelvic area; CA 125 test is used to evaluate the mass and order further ... Get accurate and quick report of CA-125 test or Cancer Antigen 125 test in Kolhapur.CA 125 test is used to monitor the ... CA 125 test is used to monitor the treatment of Ovarian Cancer. It is also used to test for recurrence of ovarian cancer. In ... Cancer Antigen 125 (CA-125) is a protein that is found on the surface of ovarian cancer cells. This makes the test useful as ...
CA 125 test is used to monitor the treatment of Ovarian Cancer. It is also used to test for recurrence of ovarian cancer. In ... CA 125 test is used to evaluate the mass and order further tests for management. ... Get accurate and quick report of Ca 125 Test Or Cancer Antigen 125 Test in titwala at your nearest Metropolis lab or your home ... CA125 levels will decline when the doctor puts you on treatment and if the treatment is working. If CA125 levels do not go down ...
CA125) and cancer antigen 15.3 (CA15.3). The results for CA125 in this data release are reported as U/mL. The results for ... Cancer antigen CA125 and CA15.3 - Serum (SSCA_B). Data File: SSCA_B.xpt. First Published: June 2019. Last Revised: NA. ... Cancer antigen 15.3 (mU/mL). English Text: Cancer antigen 15.3 (mU/mL). Target: Females only 20 YEARS - 150 YEARS. Code or ... Human CA125 (single spot, catalog number K151WC) The linearity range for the CA125 was 10,000-0.6 U/ml (low limit of detection ...
Antigens are peptides or recombinant or native dependent on the production method. ...
James Lanier is treating Asbestosis, Laryngeal Cancer, Lung Cancer, Ovarian Cancer, Pericardial Mesothelioma , Peritoneal Mesothelioma, Pleural Effusions, Pleural Mesothelioma, Pleural Plaques, Pleuritis, Testicular Mesothelioma To request an appointment with James Lanier call us at (435) 200-5326.
Barbara Herfel is treating Asbestosis, Clubbed Fingers, Diffuse Pleural Thickening, Laryngeal Cancer, Lung Cancer, Ovarian Cancer, Pericardial Mesothelioma , Pericardial Mesothelioma , Pleural Mesothelioma, Pleuritis, Rounded Atelectasis, Testicular Mesothelioma To request an appointment with Barbara Herfel call us at (435) 200-5326.
To get results back for an STD test that requires laboratory testing usually takes about a week, according to Rutgers Medical Services. Not all tests for STDs require laboratory testing, however, and...
What Is Considered Positive for a CA-125 Cancer Antigen Test?. * Q: What Is Social Anxiety?. ...
CA 19-9 Cancer Antigen This test measures the CA 19-9 levels in the blood. It is used as a tumor marker to monitor treatment ... CA 15-3 Cancer Antigen Measures the CA 15-3 levels in the blood - used as a tumor marker to monitor treatment and determine ... and several cancer antigen tests to track treatment response including the CA 125 cancer antigen test to monitor ovarian cancer ... CEA Carcinoembryonic Antigen This test is useful for identifying colon cancer recurrences after tumors have been surgically ...
  • Previous studies have indicated that plasma concentrations of chromogranin A (CGA), cytokeratin 19 fragments (CYFRA 21-1), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in healthy individuals, and this can make interpretation of results more complicated. (
  • There are two common oncofetal antigens, alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA). (
  • Carcinoembryonic antigen CA 72-4 is a more recently discovered oncofetal antigen just coming into usage. (
  • 002139 - Carcinoembryonic antigen (CEA) is a protein found in many types of cells but associated with tumors and the developing fetus. (
  • HealthCheckUSA offers a prostate cancer screening (PSA), and several cancer antigen tests to track treatment response including the CA 125 cancer antigen test to monitor ovarian cancer, and the CEA carcinoembryonic antigen for recurrence of colon cancer. (
  • Carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), cancer antigen 19-9 (CA 19-9), cancer antigen 27.29 (CA 27.29). (
  • Carcinoembryonic antigen (CEA) is a family of 36 different glycoproteins whose function is believed to be involved in cell adhesion. (
  • A comprehensive screen for 5 cancer markers including Carcinoembryonic Antigen (CEA), Cancer Antigen 19-9, Cancer Antigen 125, Alpha-Fetoprotein (AFP) and Cancer Antigen 15-3 (CA 15-3). (
  • The pre-coated antibody is Mouse CA125 monoclonal antibody and the detecting antibody is polyclonal antibody with biotin labeled. (
  • The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact CA125 molecule is used for solid phase immobilization (on the microtiter wells). (
  • CA125 is a mucin-like glycoprotein with a molecular weight over 200 kDa, which was first discovered over 30 years ago using the OC125 monoclonal antibody, 1 providing the basis for assays to detect and monitor the progression of epithelial ovarian cancer. (
  • Competition assays have demonstrated that monoclonal antibody clone M11 does not compete with monoclonal antibody clone OC125 for binding to the CA 125 antigen (7). (
  • CA-125 was initially detected using the murine monoclonal antibody designated OC125. (
  • Lee Biosolutions is the leading supplier of Cancer Antigen 125 (CA-125, MUCIN 16) for ovarian cancer research and biomarkers for manufacturing. (
  • Conclusion: CA 125 is not a strong enough predictor to be used as an indicator in lung cancer screening alone, however it may be useful in a panel of complimentary biomarkers. (
  • Future research is needed to explore whether a panel of complimentary biomarkers including CA 125 can improve lung cancer risk prediction. (
  • 140293 - Quantitative measurement of Cancer Antigen 27.29. (
  • CA 27.29 is a glycoprotein product of the muc-1 gene. (
  • The Cancer Antigen 27.29 blood test is used to monitor patients with breast cancer. (
  • In serum, CA125 is associated with a high molecular weight glycoprotein. (
  • CA 125 Antigen is a heterogonous glycoprotein. (
  • CA 125 or Muc16 is a glycoprotein member of the mucin family and is present in normal endometrial tissue. (
  • Recognizes a mucin-like glycoprotein larger than 200 kDa, expressing the CA 125 epitope. (
  • Prostate specific antigen (PSA) is a glycoprotein produced exclusively in the prostate gland. (
  • Small volumes of CA125 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. (
  • MBS264824 is a ready-to-use microwell, strip plate Quantitative Sandwich ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Carbohydrate Antigen 125 (CA125) ELISA Kit target analytes in biological samples. (
  • The ELISA analytical biochemical technique of the MBS264824 kit is based on CA125 antibody-CA125 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect CA125 antigen targets in samples. (
  • The ELISA Kit is designed to detect native, not recombinant, CA125. (
  • The CA125 ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. (
  • Should the Human Carbohydrate Antigen 125 (CA125) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement. (
  • Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 125 (CA125) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. (
  • Known also as Carbohydrate Antigen 125 elisa. (
  • This antibody detects human CA-125 in the direct ELISA. (
  • Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Carbohydrate Antigen 125 (CA125) in serum, plasma, tissue homogenates and other biological fluids. (
  • Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Mouse Carbohydrate Antigen 125 (CA125) in samples from serum, plasma, tissue homogenates and other biological fluids with no significant corss-reactivity with analogues from other species. (
  • A rabbit anti-CA125 antibody conjugated to horseradish peroxidase (HRPO) is in the antibody-enzyme conjugate solution. (
  • When the biofluid sample was passed on the CA-125 antibodies that are immobilized on the gold interdigitated electrodes, the capacitance variation of the sensing circuit was caused due to the antigen - antibody interaction. (
  • However, the capacitance measured during CA-125 antigen - antibody interaction with the microfluidic flow condition (270.34 pF) was lower than static drop condition (296.09 pF) due to the instability of the immobilized antibodies on the sensing surface that was caused by the shear stress on the sensing surface during the microfluidic flow. (
  • In addition, this study demonstrates the use of gold nanoparticles to enhance the sensor signal response and provides experimental results of the capacitance difference during cancer antigen-125 (CA-125) antigen-antibody conjugation at multiple concentrations of CA-125 antigens. (
  • The capacitive signal response of antigen-antibody conjugation on interdigitate electrodes has been enhanced by approximately 2.8 times (from 260.80 to 736.33 pF at 20 kHz frequency) in static drop condition and approximately 2.5 times (from 205.85 to 518.48 pF at 20 kHz frequency) in microfluidic flow condition with gold nanoparticle-coating. (
  • In Western blotting, the antibody labels multiple antigenic species including the molecular species recognized by monoclonal anti-CA 125, clone OC125 (7). (
  • The protein was named "cancer antigen 125" because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied. (
  • A new tumor marker , human epididymis protein 4 (HE4) , may be ordered along with CA-125 to monitor epithelial cell tumors, the most common type of ovarian cancers . (
  • Cancer antigen 125 (CA125) is a protein found on most ovarian cancer cells that is secreted into the blood stream and can be measured. (
  • A CA125 test is a blood test that measures the amount of CA125 protein in the blood. (
  • Cancer antigen 125 (CA-125) is a protein found on the surface of many ovarian cancer cells. (
  • A CA-125 test measures the amount of this protein in the blood. (
  • A label-free and array-based optical liquid-crystal (LC) immunodetection technique for the detection of CA125 antigen, a protein biomarker most frequently used for ovarian cancer detection, was demonstrated with a nematic LC with larger birefringence ( Δ n ) to promote sensitivity in detecting biomolecules. (
  • The aim of this study was to analyze the diagnostic value of the tumor markers, including risk of malignancy index (RMI), human epididymis protein 4 (HE4), cancer antigen125 (CA125), and risk of ovarian malignancy algorithm (ROMA) in ovarian mass. (
  • these markers include human epididymis protein 4 (HE4), risk of malignancy index (RMI), cancer antigen125 (CA125), and risk of ovarian malignancy algorithm (ROMA) ( 8 ). (
  • CA 19-9 is a protein found on the surface of some cancer cells. (
  • Cancer antigen 125 (CA-125) is a protein found in ovarian cancer cells. (
  • CA-125 (cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) also known as mucin 16 or MUC16 is a protein that in humans is encoded by the MUC16 gene. (
  • The Cancer Antigen (CA) 19-9 test is often used to aid in the diagnosis of Pancreatic Cancer . (
  • The Female Ultimate Anti-Aging Panel is our Ultimate Anti-Aging Panel, with the addition of Progesterone and the Cancer Antigen (CA) 125 test. (
  • High levels of cancer antigen (CA)-125 were detected in 6 of 15 patients. (
  • Often the high CA-125 level is found many months before the return of cancer can be found in another way. (
  • For example, a woman with ovarian cancer may have a high CA 125 level when she is first diagnosed. (
  • In addition, serial serum CA 125 levels were determined in 30 women with an initially elevated CA 125 level (30 U/mL or more) and 30 women with a CA 125 level less than 30 U/mL. (
  • It was found that an elevated CA 125 level was associated with a higher risk of lung cancer in individuals who smoked. (
  • MUC16 (CA-125) has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms. (
  • The region (residues 296-359) consisting of 64 amino acids at the N-terminus of cell surface mesothelin has been experimentally established as the functional binding domain (named IAB) for MUC16/CA125. (
  • CA-125 is sometimes used along with transvaginal ultrasound to test and monitor women who have a high risk for ovarian cancer but who do not yet have the disease. (
  • Sometimes a CA-125 test may be ordered along with a transvaginal ultrasound to help investigate a lump in woman's lower abdominal area (pelvic mass. (
  • Some healthcare providers may order a CA-125 test and a transvaginal ultrasound at regular intervals when a woman is at high risk of developing ovarian cancer. (
  • If you have a high risk for ovarian cancer, your doctor may recommend that you have the CA-125 blood test along with a transvaginal ultrasound on a regular basis. (
  • But some doctors may recommend the CA-125 test and a transvaginal ultrasound for women who have a very high risk of ovarian cancer, such as those with BRCA gene changes. (
  • In patients with a family history of breast or ovarian cancer this marker - CA 125should be evaluated every 6 months, along with transvaginal ultrasound performed every year for early detection of ovarian cancer. (
  • Minor complications with screening: 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with transvaginal sonogram (TVS). (
  • Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality. (
  • Intervention The intervention group was offered annual screening with CA-125 for 6 years and transvaginal ultrasound for 4 years. (
  • The usual care group was not offered annual screening with CA-125 for 6 years or transvaginal ultrasound but received their usual medical care. (
  • Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. (
  • Annual screening with CA-125 and transvaginal ultrasonography did not reduce ovarian cancer incidence or mortality. (
  • For patients with hereditary nonpolyposis colorectal cancer syndrome or hereditary breast and ovarian cancer syndrome who choose not to undergo prophylactic bilateral salpingo-oophorectomy, the National Comprehensive Cancer Network recommends transvaginal ultrasonography and CA 125 measurement every six months during days 1 through 10 of the menstrual cycle. (
  • A very high level of CA-125 is something the doctor will want to look into, but it doesn't always mean you have ovarian cancer. (
  • If the level of CA-125 is going down, it usually means that the treatment is working. (
  • Women who continued their first trimester of pregnancy showed a significantly higher number of previous abortions and progesterone level (43.12±20.85 vs. 19.26±11.8, P = 0.01) and lower level of CA 125 (34.9±11.053 vs. 61.9±19.21, P = 0.022) when compared with those who aborted. (
  • CA 19-9 is a carbohydrate antigen used for post-therapeutic monitoring of patients with gastrointestinal, pancreatic, liver, and colorectal cancer. (
  • Since its discovery in 1981 by Bast and colleagues ( 3 ), carbohydrate antigen 125 (CA125) still remains the gold-standard serum biomarker for ovarian cancer. (
  • Include markers defined by both monoclonal antibodies and polyclonal antisera, often the so called oncofetal antigens. (
  • The test sample is allowed to react simultaneously with the two antibodies, resulting in the CA125 molecules being sandwiched between the solid phase and enzyme-linked antibodies. (
  • These tests typically identify "antigens," or abnormal substances in the blood that cause the immune system to produce antibodies against it. (
  • CA 125 determination is used mainly for diagnosis and monitoring of ovarian cancer. (
  • If you are not being treated for ovarian cancer, and your results show high CA-125 levels, your health care provider will probably order more tests to help make a diagnosis. (
  • CA125 is approved for both monitoring treatment with chemotherapy and differential diagnosis of patients presenting with a pelvic mass. (
  • Easy, convenient and time-saving method to assay CA-125. (
  • The QC pool for this assay was prepared by pooling a small volume (5 ul/ sample) from over 2000 serum samples which had shown well measurable levels of CA125 in a prior study using the MSD platform. (
  • That's because not all ovarian cancers cause CA-125 levels to rise. (
  • This test is not recommended as a screening test for ovarian cancer because CA125 can be normal in many women with early stage ovarian cancer and it may be higher than normal in non-cancerous (benign) conditions and other cancers. (
  • An increased CA125 value can occur in both cancers and non-cancerous conditions. (
  • A CA 125 test may be used to monitor certain cancers during and after treatment. (
  • Measures the CA 15-3 levels in the blood - used as a tumor marker to monitor treatment and determine recurrence of metastatic breast cancer, though it may be used to track certain other cancers of the lung, pancreas, liver, colon or ovaries. (
  • CA-125 has found application as a tumor marker or biomarker that may be elevated in the blood of some patients with specific types of cancers, or other conditions that are benign. (
  • If CA-125 levels fall during therapy, this generally indicates that the cancer is responding to treatment. (
  • If CA-125 levels rise or stay the same, then the cancer may not be responding to therapy. (
  • High CA-125 levels after treatment is complete may indicate that the cancer has come back. (
  • 80% or more of women with ovarian cancer have high levels of CA-125. (
  • And you also can have higher-than-normal levels of CA-125 without having ovarian cancer . (
  • Also, healthy, normal tissue in the cells of the ovaries, pancreas , breast , and lining of the chest and stomach make and release low levels of CA-125. (
  • If you are being treated for ovarian cancer and your CA-125 levels go down during this time, it usually means your treatment is working. (
  • Very high levels of CA-125 after you finish ovarian cancer treatment could be a sign that the cancer has returned. (
  • High levels of CA-125 are a strong sign that the cancer started in the ovary. (
  • But other types of cancer can increase CA-125 levels too. (
  • Published studies have indicated that elevated serum CA125 levels can be found in individuals with serious endometroid, clear-cell and undifferentiated ovarian carcinoma. (
  • Levels of specificity suitable for screening asymptomatic postmenopausal women can be achieved using tumor-associated antigens measured serially or in combination. (
  • CA125 levels will decline when the doctor puts you on treatment and if the treatment is working. (
  • If CA125 levels do not go down during therapy, it means your treatment is not adequate. (
  • Sometimes CA125 levels are higher if a woman has a pelvic mass and if she may develop ovarian cancer in the future. (
  • Sera from residual specimens from NHANES 2001-2002 participants were tested for levels of cancer antigen 125 (CA125) and cancer antigen 15.3 (CA15.3). (
  • Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. (
  • This test measures the CA 19-9 levels in the blood. (
  • Results: Women with threatened abortion showed a significantly higher number of previous abortions and CA 125 levels (47.82±30.93 vs. 30.08±19.21, P =0.36) and lower rate of pregnancy continuation (76 vs. 90%, P = 0.044) when compared to controls. (
  • Screening with TVU alone or with multimodal screening with CA-125 levels, assessed using the ROCA, combined with TVU in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did not show a mortality benefit of screening with either approach based on a predetermined primary endpoint among women undergoing 7 to 11 screens and a median of 11.1 years of follow-up. (
  • Absence of detectable levels of CA 125 does not rule out the presence of tumor. (
  • Because not every person with pancreatic cancer will show elevated levels of CA 19-9, this test will not always be an effective tumor marker. (
  • CA-125 levels are high in many women with ovarian cancer . (
  • Because high CA-125 levels can be a sign of other conditions besides ovarian cancer, this test is not used to screen women at low risk for the disease. (
  • If testing shows your CA-125 levels have gone down, it usually means the cancer is responding to treatment. (
  • If you have finished your treatment for ovarian cancer, high CA-125 levels may mean your cancer has come back. (
  • If you are not being treated for ovarian cancer and your results show high CA-125 levels, it can be a sign of cancer. (
  • The Men's Expanded Cancer Panel is a panel of blood tests that includes the CEA and the PSA test to detect antigens and read blood hormone levels. (
  • After treatment, her levels of CA 125 should fall. (
  • 1985) Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. (
  • The standard clinical cutoff value for CA125 is 35 U/mL, although serum levels have been shown to fluctuate depending on race, menstrual cycle time point, and presence of non-ovarian cancer pathologies ( 4-7 ). (
  • Testing of CA-125 blood levels has been proposed as useful in treating ovarian cancer. (
  • While the test can give useful information for women already known to have ovarian cancer, CA-125 testing has not been found useful as a screening method because of the uncertain correlation between CA-125 levels and cancer. (
  • The oncofetal antigens are so named because they are normally produced during embryonic development and decrease soon after birth. (
  • Cancer Antigen 125 (CA125) is a surface antigen associated with epithelial ovarian cancer. (
  • To date, CA125 is the most sensitive marker for residual epithelial ovarian cancer. (
  • Multifocal staining for neuron specific enolase (NSE) and mesothelin and focal high molecular weight (HMW)+low molecular weight cytokeratin (CK), epithelial membrane antigen (EMA), synaptophysin (SYNP), WT1 positivity was detected (Figure 1, 2). (
  • CA 125 antigen derived from ascites fluid. (
  • The usage of tumor marker CA125 alone is associated with serious limitations like low sensitivity for early or stage I disease and lack of specificity especially in pre-menopausal women. (
  • The CA-125 test looks for certain proteins in your blood . (
  • To investigate the benefit of early chemotherapy for recurrent ovarian cancer based on a raised CA125 (a serum marker) level alone, versus chemotherapy based on conventional clinical indicators. (
  • A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. (
  • The concentration gradients of the kit standards or positive controls render a theoretical kit detection range of 100 U/ml-1.56 U/ml in biological research samples containing CA125, with an estimated sensitivity of 0.5 U/ml. (
  • The determination of CA 19-9 cannot be used for the early detection of pancreatic carcinoma. (
  • The linearity range for the CA125 was 10,000-0.6 U/ml (low limit of detection (LLD) 0.286 U/ml). (
  • Women were enrolled in the Gilda Radner Ovarian Cancer Detection program at Cedars-Sinai Medical Center, Los Angeles, California from July 1, 1991, to July 1, 1993. (
  • The experimental results also provide evidence of disease-specific detection of CA-125 antigen at multiple concentrations with the increase in capacitive signal response proportional to the concentration of the CA-125 antigens. (
  • The test for CA-125 may also be done on body fluids (other than blood) taken from the chest or stomach area. (
  • The CA-125 test quantifies and is a measure of the amount of CA125 in the blood. (
  • What is a CA-125 blood test? (
  • A CA-125 blood test is most often done on women already diagnosed with ovarian cancer. (
  • Why do I need a CA-125 blood test? (
  • You may need a CA-125 blood test if you are currently being treated for ovarian cancer. (
  • You don't need any special preparations for a CA-125 blood test. (
  • Is there anything else I need to know about a CA-125 blood test? (
  • A test for a tumor marker called HE4 may be done along with a CA-125 blood test. (
  • Get cancer blood testing labs and get same day testing from FDA approved labs near Santa Maria CA. (
  • A CA-125 blood test to measure the amount of cancer-antigen 125 in your blood. (
  • Walk-In Lab offers several cancer blood tests such as the Cancer Screening Panel, Women, the CA 15-3, and the CA 125. (
  • Because CA-125 can be high in many normal or benign conditions, such as pregnancy , menstruation, endometriosis , and pelvic inflammatory disease , it is not useful or recommended as a screening test for the general population. (
  • Experts do not recommend using the CA-125 test as a screening test for ovarian cancer because it often has false-positive results that can lead to unneeded surgery. (
  • Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. (
  • To assess different strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens, including concomitant measurement of multiple tumor markers and serial measurement of CA 125. (
  • A combination of CA 125, CA 15-3, and TAG 72.3 was evaluated in serum samples from 217 of 1010 apparently healthy postmenopausal women who had participated in a study of screening for ovarian cancer and who had a serum CA 125 level of 20 U/mL or greater. (
  • CA 125 cannot be used for ovarian cancer screening in the general population because of its lack of sensitivity for early stage disease. (
  • There is solid evidence to indicate that screening women aged 55 to 74 years at average risk of developing ovarian cancer with the serum marker CA-125 (at a fixed threshold for a positive result of 35 U/mL) annually for 6 years and TVU for 4 years does not result in a decrease in ovarian cancer mortality, after a median follow-up of 14.7 years. (
  • While a CA 19-9 test can be used to differentiate types of cancer or monitor response to treatment, it is not sensitive enough to be used as an initial screening by itself. (
  • If you answered yes to any of them, you would be wise to look into cancer screening near Santa Maria, CA. (
  • Why is regular cancer screening near Santa Maria, CA so important? (
  • High values of CA-125 in a woman who has been treated for ovarian cancer may mean that the cancer has returned. (
  • Recently, chimeric antigen receptor (CAR) T cell therapy has shown promising results in hematological tumors and current research is going on in various solid tumors like ovarian cancer. (
  • Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. (
  • Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. (
  • Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. (
  • 002261 - The CA 19-9 is used to monitor gastrointestinal, pancreatic, liver and colorectal malignancies. (
  • Cancer antigen 125 (CA-125) and serum progesterone as predictors of fate of threatened abortion: Case control study', Evidence Based Women's Health Journal , 7(4), pp. 177-183. (
  • Objective: To investigate the predictive value of serum progesterone and CA-125 regarding pregnancy continuation in women with threatened abortion. (
  • Group II included 100 women with normal asymptomatic pregnancy.CA 125 and serum progesterone were measured in all women. (
  • Conclusion: CA125 and progesterone are good predictors for the outcome of 1st trimester of pregnancy in both normal women and those with threatened abortion. (
  • The specificity of CA 125 at upper limits of 30 and 50 U/mL was increased from 97.0 and 99.5%, respectively, to 98.9 and 99.9% when a positive test was defined as an elevated serum CA 125 level in combination with either a CA 15-3 greater than 30 U/mL or a TAG 72.3 greater than 10 U/mL. (
  • Serial determinations of serum CA125 as well as pelvic examination increase the test specificity. (
  • The evaluation of the area under the curve (AUC) for isolated CA-125 and HE4, and for ROMA and RMI-II, showed a better specificity of HE4 and RMI-II in premenopausal women. (
  • As such, a major limitation of CA125 is that it displays poor specificity for ovarian cancer overall ( 8-10 ). (
  • The CA-125 test may be ordered before a woman starts ovarian cancer treatment as a baseline to compare against future measurements. (
  • The minimum detectable concentration of CA-125 is less than 0.6 U/ml. (
  • One hundred patients with ovarian masses were assessed for the tumor markers ROMA, HE4, RMI, and CA125. (
  • The results based on the AUC markers of CA125, HE4, RMI, and ROMA revealed that the accuracy trend of ROMA was higher than that of CA125, HE4, and RMI in all the patients and each group of pre- and post-menopausal patients. (
  • The markers identified through our integrated -omics approach performed similarly to the clinically approved markers CA125 and HE4. (
  • Cancer Antigen 125 (CA-125) is a tumor marker primarily used to monitor therapy during treatment for ovarian cancer . (
  • CA-125 is also used to detect whether cancer has come back after treatment is complete. (
  • Your doctor may order a CA-125 test if you're about to start treatment for ovarian cancer . (
  • A decrease in the CA125 level during treatment usually means that the cancer is responding to treatment. (
  • If the CA125 level stays the same or rises during treatment, it may mean that the cancer is not responding to treatment. (
  • A high CA125 level after treatment is complete may mean that the cancer has come back (recurred). (
  • Most often, the CA-125 test is used to check how well treatment for ovarian cancer is working or to see if ovarian cancer has returned. (
  • Following a raised CA125 result patients are randomised to receive either delayed treatment until patient shows clinical signs of relapse or immediate treatment which must start within 4 weeks. (
  • Serum CA125 concentration may be useful in monitoring treatment and distinguishing between good response to treatment and progressive malignant disease with poor therapeutic response. (
  • CA 125 test is used to monitor the treatment of Ovarian Cancer. (
  • In a woman with a pelvic mass, and in a woman with a high risk for developing ovarian cancer, a significantly elevated CA-125 is a concern but does not necessarily indicate ovarian cancer. (
  • Results: The study demonstrated that CA 125 is significantly and independently associated with lung cancer and that CA 125 is associated with early-stage lung cancer. (